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ABSTRACT 
 
MARKERS AND MECHANISMS OF METABOLIC AGING 
Peter D. Ahiawodzi 
April 17, 2014 
Oxidative stress has been implicated in aging and age-related diseases. Using 
three distinct studies, this dissertation examines associations between lifestyle factors and 
oxidative stress, and their effects on advanced glycation end products, telomere length, 
and type II diabetes.    
Carboxymethyl-lysine (CML), an advanced glycation end-product, has been 
linked to oxidative stress, cardiovascular and other age-related diseases. The first study 
investigates the association between sleep disordered breathing (SDB), a source of 
oxidative stress, and CML. 1002 participants with sleep data from the Cardiovascular 
Health Study (CHS) were analyzed. SDB was not significantly associated with CML, but 
after stratification by gender and hemoglobin it was found that among female subjects 
with higher hemoglobin levels, those with more severe SDB had a significantly higher 
CML concentration, while the reverse was observed among males.   
Telomere length is another biomarker of cumulative exposure to oxidative stress 
and an indicator of aging. In the second study, 974 participants from the Framingham
vi 
 
Heart Study were analyzed to investigate the role of modifiable factors known to affect 
oxidative stress including obesity, cigarette smoking, excessive alcohol consumption, and 
physical inactivity, on telomere length. Age, gender, BMI, and alcohol consumption were 
found to significantly influence telomere length.  
Diabetes and its complications have roots in oxidative stress. Sleep disturbance, 
especially sleep apnea, is a potential source of oxidative stress. A total of 9635 
participants in the first National Health and Nutrition Examination Survey were followed 
from 1982 to 1992. Time to diabetes was modeled as a function of sleep quality and 
quantity with adjustment for potential confounders. Sleep quality, but not sleep quantity, 
was significantly associated with type II diabetes.   
In conclusion, oxidative stress plays a vital role in aging and age-related diseases. 
This dissertation emphasizes the importance of good sleep hygiene, healthy weight, and 
moderate alcohol consumption to curb the burden of oxidative stress on the human 
system. These findings may be considered in the policy framework of interventions 
aimed at reducing age-related diseases, to promote healthier aging and longevity.  
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CHAPTER ONE 
BACKGROUND 
1.1 Evolutionary Theories of Aging 
 
Aging is a major contributor to Alzheimer’s disease, atherosclerosis, osteoporosis 
and autoimmune diseases1. Why and how organisms age is still not fully understood. 
Weismann et al.,2 proposed that aging is a death-mechanism, an adaptive response to 
exclude old members of population on a schedule responsive to new propagation, 
primarily under selection against overcrowding. Another school of thought suggests that 
late-acting deleterious effects of accumulated mutations in the cells of organisms 
contribute to aging of the organism. This is known as the somatic mutational theory and 
was proposed by Smith in 1962 when he used ionizing radiation to argue that radiation 
causes genetic mutations and shortens lifespan, and could serve as a major force in 
aging3. 
More recently, disposable soma theory was proposed to explain variation among 
species in characteristic lifespan. The theory considers lifespan a trait evolved by 
selection primarily on the energetic requirements of complex organisms. Under the 
theory, the somatic self of an organism is a system of high energy demand for both 
reproductive and non-reproductive activities. From birth to death the molecular processes
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of DNA replication and repair, protein synthesis and replenishment, require considerable 
energy expenditure, and lifespan is viewed as an average balance in tradeoffs between 
energy costs and investments that sustain the somatic and behavioral functions of an 
organism, at least through reproduction. Post-reproductively selection pressure falls off, 
and with the passage of time, the energetic maintenance of these basic systems declines 
causing systemic defects to accumulate and manifest as aging, or senescence of the 
organism4-6.  
1.2 The Free Radical Theory of Aging    
The free radical theory of aging was first proposed by Harman in 1956 and states 
that lifespan is mainly dependent on the production of intracellular reactive oxygen 
species (ROS)7. This theory is based on the premise that the harmful effects of ROS on 
various cells and organs results in their functional deterioration, and are often expressed 
as general decline and/or diseases associated with advancing age. The theory was 
expanded later to identify mitochondrial production of O2•- and H2O2 as the main source 
of ROS production causing age-related damage and organ dysfunction8.  
1.3 Mitochondrial DNA and Reactive Oxygen Species 
Mitochondria are present by the hundreds in every human cell, and each 
mitochondrion contains multiple small circular genomes (mtDNA). Mitochondria are the 
sites within cells of energy production and transport, where food and oxygen intake 
generate chemical energy and heat for work and maintenance of body temperature. This 
process of oxidative phosphorylation (OXPHOS) to produce energy (ATP) occurs by 
oxidizing hydrogen from consumed carbohydrates and fats in an ordered sequence of 
3 
 
electron transport: electrons from NADH+H+ or from succinate are donated to NADH or 
succinate dehydrogenase, then passed to coenzyme Q (CoQ) to produce ubisemiquinone 
(CoQH•),  then ubiquinol (CoQH2), and to cytochrome c oxidoreductase (complex III). 
Electrons are then transferred from complex III to IV, also known as cytochrome oxidase, 
where 1/2O2 is produced and finally H2O. It is the flow of electrons through this transport 
chain (ETC) that releases energy which in turn pumps protons out of the inner membrane 
of the mitochondria creating an electrochemical gradient which also captures energy to 
aid ATP release. The mitochondria in turn generate (ROS) as by-products of the energy 
production process: these include superoxide anion, hydrogen peroxide, and highly 
reactive hydroxyl radical. These free radicals then inflict damage on the mitochondria, 
mtDNAs, and the cell with downstream pathological consequences including 
hypertension, atherosclerosis, and diabetes9-12. 
Retention of electrons in the initial steps of the ETC generate ROS as by-products 
when unpaired electrons at CoQ binding-sites of complexes I, II, and III are directly 
donated to O2 to generate superoxide anion (O2•-), then converted to H2O2 in the presence 
of Manganese superoxide dismutase (MnSOD). Finally, H2O2 converts to the highly 
reactive hydroxyl radical (OH•) in the presence of iron or other transition metals9, 13, 14.  
Retention of electrons in the ETC occurs when calories are consumed in excess of the 
demand for their use, or with lack of exercise. Caloric intake without compensatory 
exercise, ramps down ATP production, causes hyperpolarization of the electrochemical 
gradient, and the eventual inhibition of OXPHOS, while leaving untransported electrons 
as free radicals available for ROS production9.    
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These reactive oxygen species could cause mitochondrial DNA mutations and 
these defects in the mitochondria could lead to dysfunction and eventually death. 
Mitochondrial production of reactive oxygen species is significantly increased in the 
heart and increases cardiac aging. This is because the heart is an organ that is very rich in 
mitochondria because of its high metabolic demand. Reactive oxygen species production 
is therefore very high in the heart making the heart very susceptible to oxidative 
damage15, 16. In support of the free radical theory of aging Schriner et al., compared mice 
that overexpressed human catalase localized to the mitochondria with wild-type litter 
mates. They found that cardiac malfunction was delayed, and H2O2 production and 
mitochondrial DNA mutations were reduced, and lifespan increased in mice 
overexpressing human catalase targeted to the mitochondria17.  Mitochondrial reactive 
oxygen species have also been linked to vascular aging by induction of apoptosis and 
studies have shown that the rate of endothelial apoptosis was increased with oxidative 
stress18, 19. Endothelium-dependent vasodilation has also been proposed to be the result of 
mitochondrial oxidative stress and can cause a drop in blood pressure sufficient enough 
to produce shock20, 21. Moreover, defects to the mitochondria as a result of reactive 
oxygen species could collapse the blood-brain barrier and lead to neuroinflammation 
associated with aging. This is because the integrity of the blood-brain barrier depends on 
the proper functioning of the mitochondria and inhibition of the mitochondrial function 
has adverse consequences for the blood-brain barrier22. 
1.4 Other Sources of Reactive Oxygen Species 
Mitochondria produce most of the endogenous reactive oxygen species23, 24. 
However various enzymes localized elsewhere within the cell are also involved in ROS 
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production, including NADPH oxidase at the plasma membrane, lipid oxidation within 
peroxisomes, and xanthine oxidase in the cytoplasm.  
1.4.1 Reactive Oxygen Species Generation by NADPH Oxidase 
The human immune system is comprised of phagocytes (neutrophils, monocytes, 
eosinophils) that fight invading pathogens with the help of antimicrobial oxidants such as 
O2•- and H2O2.  NADPH oxidase is responsible for the generation of these antimicrobial 
oxidants. NADPH oxidase is activated when cells come into contact with bacteria or 
other inflammatory stimuli and catalyzes the reduction of oxygen to O2•- to kill bacteria25. 
The superoxide anion can undergo further reactions to form the more potent hydroxyl 
radical (OH•). This can happen in two ways: by the Fenton mechanism (Fe2+ + H2O2 → 
Fe3+ + OH• + OH-) or the Haber–Weiss mechanism (O2•- + H2O2 → OH• + OH- + O2; 
catalyzed by Fe3+)26. Release of these oxidants is essential for immune system function, 
but excessive release can cause inflammatory tissue injury and eventual dysfunction of 
the associated organs27. 
1.4.2 Reactive Oxygen Species Generation by Xanthine Oxidase 
The phenomenon of the “oxygen paradox” proposed that post-ischemic tissue 
injury is mainly attributed to free radical production during reoxygenation28-30. In 
ischemic states like myocardial infarction and stroke there is severe restriction of blood 
flow to tissues and the immediate medical solution is to restore oxygen. However, 
depending on the duration of the ischemia it has been found that tissue damage occurs as 
a result of reoxygenation of the ischemic tissues. There are two processes that lead to free 
radical production in post-ischemic tissues. Firstly, Ischemic conditions enable the 
conversion of xanthine dehydrogenase to xanthine oxidase. Secondly, in ischemia there is 
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depletion of ATP to AMP. Catabolism of AMP eventually leads to accumulation of 
hypoxanthine which is the substrate for the enzyme xanthine oxidase. Xanthine oxidase 
then catalyzes the oxidation of hypoxanthine to xanthine and further catalyzes the 
oxidation of xanthine to uric acid, and molecular oxygen (in reperfusion) to O2•- and 
H2O2. Further reactions in the ischemic tissue promote the formation of OH• via the 
Fenton mechanism. This increased free radical production in ischemic diseases such as 
stroke and myocardial infarction has therefore been proposed as a major factor in 
reperfusion-induced injury26, 31.  
1.4.3 Reactive Oxygen Species Generation by Lipid Oxidation 
Peroxisomes are membrane-bound organelles that are present in the cytoplasm of 
all eukaryotic cells. They are involved in metabolism and contain enzymes that oxidize 
fatty acids and amino acids. As part of the peroxisomal metabolism reactive oxygen 
species are produced. Peroxisomal enzymes such as acyl-CoA oxidase, D-amino acid 
oxidase, and xanthine oxidase produce H2O2 which can undergo the Fenton reaction to 
produce the more potent hydroxyl radical32. Peroxisomes also contain the enzyme 
catalase, the most abundant peroxisomal antioxidant enzyme, which decomposes H2O2 to 
water, hence peroxisomes are protective against oxidative stress in the cell. Increased risk 
of  age-related diseases including diabetes, atherosclerosis, and cancer have been found in 
individuals deficient in the enzyme catalase33. Oxidative stress occurs when the 
production of reactive oxygen species in the peroxisome exceeds that which can be 
adequately detoxified34, 35. The xanthine oxidase in the peroxisome can also reduce 
nitrates and nitrites to NO•36. However NO• can react with O2•- to produce ONOO- which 
is a strong oxidizing agent and capable of rendering peroxisomal enzymes inactive37. 
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This also leads to decrease in nitric oxide bioavailability. Nitric oxide is vasodilatory in 
function and therefore has antiproliferative effect on smooth muscle cells. Depletion of 
nitric oxides leads to vascular thickening and loss of elasticity and hence endothelial 
dysfunction38. 
1.5 Advanced Glycation End-Products  
Advanced glycation end products (AGEs) are a heterogeneous group of 
macromolecules that are formed by the nonenzymatic glycation of proteins, lipids, and 
nucleic acids. AGE formation induces oxidative stress which indirectly causes more 
AGEs production39, 40. AGEs have been implicated in pathologies such as diabetic 
microvascular disease, connective tissue diseases (esp. rheumatoid arthritis), Alzheimer’s 
disease, end-stage renal disease, hypertension, atherosclerosis and many other age-related 
disorders39. Accumulation of AGEs occurs with age and as part of normal metabolic 
processes. However, accelerated production is associated with diabetes due to 
hyperglycemia and leads to vascular damage and eventual microvascular complications 
such as neuropathy, nephropathy, and retinopathy39, 41. Carboxymethyl-lysine (CML), a 
well characterized AGE, is formed on protein by combined nonenzymatic glycation and 
oxidation reactions, and also during metal-catalyzed oxidation of polyunsaturated fatty 
acids in the presence of protein (lipid peroxidation). CML is characterized as a general 
biomarker of oxidative stress and damage in tissue proteins42. 
1.5.1 Hypoxia, Lysyl Oxidase Activity, and Carboxymethyl-lysine 
Collagen is the protein that forms connective fibers in tissues. Collagen fibers 
keep bones and blood vessels strong. Collagen is also required for the repair of blood 
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vessels. It is the main component of connective tissue, and is the most abundant protein 
in mammals43. Elastin is a major component of the extracellular matrix. It is a protein in 
connective tissue that is elastic and allows tissues in the arterial wall to resume their 
shape after stretching or contracting. Degradation of elastin in arterial walls is a 
characteristic feature of atherogenesis44. The biomechanical properties of the vessel wall 
are determined largely by the extracellular matrix proteins collagen and elastin. The 
degree of cross-linking is a critical feature of collagen and elastin fibers. The cross-links 
in collagen contributes to the stiffness of collagen fibers45, whereas the cross-links in 
elastin are important for the rubber-like properties of elastin fibers46.  
Lysyl oxidase catalyzes the covalent cross-linking of collagen and elastin in the 
extracellular space by oxidizing specific lysine residues in these proteins. The cross-
linking of collagen and elastin stabilizes these proteins and also helps in the formation 
and repair of the extracellular matrix. Thus lysyl oxidase activity is essential in 
maintaining the tensile and elastic features of connective tissues of many systems 
including the pulmonary system47. Downregulation of lysyl oxidase has been associated 
with endothelial dysfunction48, 49. However, overexpression of lysyl oxidase has been 
associated with pulmonary arterial stiffness in hypertension50 , atrial fibrillation51, and in 
tumor initiation and progression52. 
It has been found that hypoxia increases lysyl oxidase gene expression levels50, 53.  
Endothelial cells respond to hypoxia by remodeling the extracellular matrix. This implies 
an upregulation of lysyl oxidase, a vital enzyme in extracellular matrix assembly. 
Furthermore, it has been found that the hypoxia-induced increase in lysyl oxidase 
expression is associated with increased levels of reactive oxygen species54.  
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These findings indicate that hypoxia in SDB disrupts lysyl oxidase activity. The 
overexpression of lysyl oxidase in the extracellular matrix is also an indication of 
increased lysine modifications including carboxymethyl-lysine (CML)55, 56. 
1.6 Oxidative Stress and Disease 
When an imbalance exist between prooxidant and antioxidants such that 
prooxidant levels exceed that of antioxidants the situation is referred to as oxidative 
stress. This can result from diminished antioxidant levels (vitamins E, C, and D, 
flavonoids and carotenoids) and micro-nutrient levels (iron, copper, zinc, and selenium). 
These micro-nutrients play vital roles in the proper functioning of antioxidant enzymes 
(copper/zinc superoxide dismutase, catalase, or glutathione peroxidase). Depletion of 
these nutrients and dysfunction of antioxidant enzymes leads to increased accumulation 
of reactive oxygen species26 from any of the mechanisms described above.  Since 
proposed by Harman in 19567, 23 oxidative stress remains the most widely accepted cause 
of aging and age-related diseases.  Oxidative stress has been associated with aging in 
humans, and diseases such as diabetes, Parkinson’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington disease, cancer, and cardiovascular disease57-64. 
Reactive oxygen species (O2•-, H2O2, and OH•) impose oxidative damage on 
important proteins, lipids, nucleic acids65-67. The hydroxyl radical has the ability to 
modify DNA bases and also cause strand breaks, leading DNA damage68. It can attach to 
the C-8 position of guanine to form 8–hydroxyguanine (8-OH-guanine) which has been 
implicated in Parkinson’s disease and Alzheimer’s disease69, 70. Another effect of 
oxidative damage on DNA bases is mutation arising from AT↔GC transition and by 
10 
 
GC↔TA transversion, which can result in changes in protein gene expression26. In 
proteins, reactive oxygen species cause damage by forming protein modifications such as 
carbonyls, dityrosine, and nitrated and chlorinated tyrosines, and these have been found 
at elevated levels in inflammatory disease patients26. In the presence of reactive oxygen 
species and oxygen, lipids undergo peroxidation in which several molecules of lipid (LH) 
are oxidized. The process involves the highly reactive hydroxyl radical extracting the 
allylic hydrogen from the lipid thereby forming a carbon-centered lipid radical (L•), 
which reacts with oxygen to form a lipid peroxy radical (LOO•). Lipid peroxidation of 
low-density lipoprotein (LDL) and subsequent accumulation of the oxidized LDL leads 
to the formation of foam cells from macrophages, the initial stage of Atherosclerosis26, 71, 
72.  
1.6.1 Oxidative Stress and Type-2-Diabetes 
The β-cells of the pancreas produce insulin which is important in glucose 
metabolism. It has been established that elevated levels of long chain saturated non-
esterified fatty acids exhibit a strong cytotoxic effect on the β-cells resulting in β-cell 
dysfunction and apoptosis73, 74. Metabolism of long chain non-esterified fatty acids in the 
peroxisomes leads to the formation of H2O2 which is thought to mediate the lipotoxicity 
of the β-cells75. The β-cells are particularly vulnerable to the toxic effects mediated by 
H2O2 because β-cells lack catalase, the enzyme responsible for decomposing H2O2 to 
water76, 77. 
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1.6.2 Oxidative Stress and Leucocyte Telomere Length  
As discussed earlier oxidative stress is associated with aging57. Telomeres have 
also been found to play a major role in human aging, raising discussions on the 
relationship between oxidative stress and telomere length78. Telomeres are repetitive 
DNA sequences that cap the ends of chromosomes. In humans, the long stretches of the 
tandem repeats are made up of TTAGGG79. Telomeres function to regulate the 
proliferation of cells in organisms. This role was made possible because telomeres 
shorten as the organism ages and this shortening place limits on the number of 
replications that the cells of the organism can undergo. The decreased proliferative 
potential of the cell due to telomere attrition may cause alterations in cellular metabolism 
and lead to apoptosis78.  
Genetic and environmental factors influence telomere length: these include 
physical activity, tobacco smoking, socio-economic status, body-mass index, alcohol 
consumption, multivitamin intake, dietary antioxidants, paternal age at time of 
offspring’s birth, and perceived stress and adverse life events. These factors may increase 
or decrease oxidative stress and inflammation, which are very important in telomere 
length dynamics and aging80-88. Eisenberg78 proposed the “thrifty telomere model” which 
states that regulation of maintenance effort in an organism is the main function of the 
telomeres. This suggests that telomeres are responsible for programming the allocation of 
resources within the organism. Hence factors like tobacco use, alcohol consumption, and 
obesity, which potentially place extra oxidative burden on the cells of the organism could 
lead to shorter telomeres because the extra oxidative burden could only be met when part 
of the soma  is lost (in this case, telomere length reduction). As telomeres become 
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shorter, the replicative capacity of the cell is reduced leading to senescence. Von 
Zglinicki in his review of oxidative stress and telomere length acknowledged that in most 
cases the replicative senescence of telomeres is a stress response arising from external 
oxidative stress or diminished internal antioxidant defenses. His review of experiments 
on stress dependency of telomere shortening revealed that 19 out of 22 independent 
experiments from seven different laboratories, showed increased telomere shortening rate 
under conditions of increased oxidative stress. He further suggested that telomere length 
might serve as a biomarker of cumulative exposure to oxidative stress and a prognostic 
indicator for risk of late-life diseases89.  
1.7 Summary 
In summary, reactive oxygen species have been widely accepted as a major 
contributor to dysfunction of biological systems resulting in aging and age-related 
diseases. In this dissertation, factors that encourage increased reactive oxygen species 
production were investigated. Sleep-disordered breathing and CML are both associated 
with oxidative stress; hence, this dissertation investigated the relationship between sleep-
disordered breathing and serum CML concentration. CML accumulation has been 
association with Alzheimer’s disease, end-stage renal disease, hypertension, 
atherosclerosis and many other age-related disorders. Understanding its association with 
sleep disordered breathing could provide avenues for prevention. In addition, we 
investigated the role of sleep and obesity on type-2 diabetes risk. Diabetes results from 
oxidative damage to insulin producing cells and research suggests that sleep disturbances 
and obesity may be involved in this process. Lastly, we investigated the effects of alcohol 
consumption and obesity on telomere length. Telomere shortening has been found to be 
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stress dependent and alcohol consumption and obesity can induce stress. Telomere 
shortening has been linked to neurodegenerative diseases, infections, diabetes, 
malignancies, atherosclerosis, and cardiovascular disease. Understanding the sources of 
stress in telomere shortening is important in the wake of the harmful effects of shorter 
telomeres on health.  
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Figure 1: Mechanisms linking oxidative stress to aging and degenerative diseases 
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CHAPTER TWO 
 
THE RELATIONSHIP BETWEEN SLEEP-DISORDERED BREATHING AND Nϵ-
CARBOXYMETHYL-LYSINE CONCENTRATION IN THE CARDIOVASCULAR 
HEALTH STUDY 
 
2.1 INTRODUCTION 
Advanced glycation end-products (AGEs) have been implicated in pathologies 
such as diabetic microvascular disease, rheumatoid arthritis, Alzheimer’s disease, end-
stage renal disease, hypertension, atherosclerosis and other late-life disorders39. Major 
AGEs include hydroimidazolone (HI), Nϵ-carboxymethyl-lysine (CML), pentosidine 
(PTD), and glucosepane39. CML is the focus in this study because it has been found to be 
a general biomarker of oxidative stress and damage in tissue proteins. CML is formed on 
protein by combined nonenzymatic glycation and oxidation reactions, and also during 
metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of protein42. 
CML has serious implications for cardiovascular disease because it has been found to be 
the main contributor to atherosclerotic plaque42, 90, 91.  Cardiovascular disease is the 
leading cause of death in the United States. More than 80 million people live with 
cardiovascular disease of some sort, and together with stroke they account for more than 
$500 billion in medical costs in 2010. It is important that the scientific community find 
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ways to reduce accumulation of advanced glycation end-products, including CML, as 
part of efforts aimed at reversing the trend of cardiovascular morbidity and mortality.  
There is a possible link between sleep-disordered breathing and serum CML 
levels because sleep-disordered breathing is accompanied by production of free radicals 
and increased oxidative stress, a condition which promotes increased CML production. In 
sleep-disordered breathing there are repeated episodes of hypoxia which leads to energy 
crisis as the production of adenosine triphosphate (ATP) is impaired leading to up-
regulation of glycolysis and consequent increased production of reactive oxygen species 
(ROS)24, 92. Sleep-disordered breathing, especially obstructive sleep apnea, can be treated 
by use of continuous positive airway pressure (CPAP)93-96. This implies that if evidence 
exists for a causal relationship, then intensification of efforts to promote sleep hygiene 
and treatment of sleep-disordered breathing could be considered as part of efforts to 
reduce CML accumulation and hence reduce cardiovascular and other age-related 
diseases. 
Few studies investigated the effect of sleep-disordered breathing on AGEs, 
broadly96, 97. A pilot study has also shown that continuous positive airway pressure 
treatment reduces serum AGEs in patients with obstructive sleep apnea syndrome98. The 
relationship between sleep disordered breathing and CML concentration however has not 
been studied. Moreover, there is evidence for increased lipid peroxidation biomarkers, an 
indication of increased state of oxidative stress, in sleep-disordered breathing 99. Since 
CML is formed from lipid peroxidation and known to be an excellent biomarker for 
oxidative stress it will be more appropriate to investigate the association between sleep-
disordered breathing and CML specifically instead of AGEs as a broad category. The 
17 
 
main aim of this study is to investigate the association between sleep-disordered 
breathing and serum CML levels in the Cardiovascular Heart Study. 
 
2.1.1 Study objectives 
1. To investigate the cross-sectional relationship between sleep disordered breathing 
(SDB) assessed by apnea-hypopnea index (AHI), and carboxymethyl-lysine 
(CML) concentration in the Cardiovascular Heart Study (CHS) cohort enrolled in 
the Sleep Heart Health Study (SHHS).   
 
2. To investigate the potential modification effects of gender and hemoglobin on the 
association between sleep disordered breathing and CML. 
 
2.1.2 Hypotheses 
1. Study subjects with SDB will have higher serum concentrations of CML. 
2.  The effect of SDB on CML concentration will vary by gender and will be higher 
in participants with higher hemoglobin levels. 
 
2.1.3 Justification of the study 
Carboxymethyl-lysine (CML), a well characterized advanced glycation end-
product has been associated with degenerative diseases including Alzheimer’s disease, 
end-stage renal disease, hypertension, atherosclerosis and many other age-related 
disorders. Pharmaceutical interventions to reduce CML accumulation have shown 
promising results but are yet to be investigated using larger populations. Continuous 
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positive airway pressure (CPAP) treatment for sleep-disordered breathing, especially 
obstructive sleep apnea, has been established. Evidence for a causal relationship between 
sleep-disordered breathing and CML could provide avenue for intervention within the 
wide range of possible interventions. 
 
2.2 METHODS 
 
2.2.1 Study Design: Population-based cross-sectional study of the association between 
sleep-disordered breathing and serum carboxymethyl-lysine. 
2.2.2 Study Participants: The subjects for this study are CHS cohort members who were 
enrolled in the SHHS. The CHS is a population-based longitudinal study designed to 
determine the risk factors for development and progression of cardiovascular disease 
(CVD) in older adults (≥65 years) in the United States. The CHS recruited 5,888 adults 
from four U.S communities: Forsyth County, North Carolina; Sacramento County, 
California; Washington County, Maryland; and Pittsburgh, Pennsylvania. The SHHS is a 
prospective cohort study designed to investigate obstructive sleep apnea (OSA) and other 
sleep-disordered breathing (SDB) as risk factors for the development of cardiovascular 
disease. Participants in SHHS were recruited from already existing cohort studies: 
Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Framingham 
Heart Study, Strong Heart Study, New York Hypertension Cohorts, and Tucson 
Epidemiologic Study of Airways Obstructive Diseases and the Health and Environment 
Study. Participants in the SHHS underwent home polysomnography to assess the 
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presence of OSA and other SDB100. This study focuses on over 1000 participants that 
were recruited from the CHS into the SHHS.  
 
2.2.3 Assessment of Sleep Disordered Breathing  
SDB was diagnosed by polysomnography and measured by apnea-hypopnea 
index (AHI). AHI is the number of respiratory events scored per hour of sleep. Apneas 
and hypopneas were classified according to the American Academy of Sleep Medicine 
(AASM) criteria. According to AASM criteria an event is classified as apnea if there is a 
drop in peak thermal sensor excursion by ≥90% from baseline, for 10 seconds or greater, 
and an event is classified as hypopnea if there is a ≥30% drop in the nasal pressure 
excursion for 10 seconds or greater associated with ≥ 4% desaturation 101, 102. AHI was 
used as a continuous variable and cut-points were also be considered.  AHI cut points for 
diagnosis are: <5/hr (normal), ≥ 5 and < 15/hr (Mild), ≥ 15 and ≤ 30/hr (moderate), and 
AHI > 30/hr (severe) 103. 
 
2.2.4 Polysomnography 
Polysomnography (PSG) or a sleep study is a test used to diagnose sleep 
disorders. It is considered to be the ‘‘gold standard’’ for diagnosing SDB and other sleep 
disorders. PSG monitors sleep stages and cycles to identify disruptions in sleep patterns. 
PSG is recommended when the following are suspected: sleep-related breathing disorder, 
periodic limb movement disorder, narcolepsy, unusual behaviors during sleep, and 
unexplained chronic insomnia. PSG is a noninvasive test. However the adhesive used to 
attach the test sensors to the skin could cause skin irritation. Alcohol and caffeine may 
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make symptoms of some sleep disorders worse and it is recommended that they are 
avoided at least 12 hours before the sleep study.  
There are two critical components of PSG: (1) determination of sleep-wake stage, 
and (2) identification of related bodily processes. Sleep-wake determination involves 
electroencephalography (EEG; records surface electrical activity of the brain), 
electrooculogram (EOG; records eye movements during sleep and wakefulness), and 
electromyography of the submentalis (EMG; recordings are essential for scoring sleep 
stages)104. The placement of these electrodes is shown by Appendices 1, 2, and . Related 
bodily processes measured in PSG include heart rate, blood pressure, and respiratory 
function. Respiratory air flow is determined by measuring inhaled and exhaled air 
temperatures by a thermistor. Thermosensors are best in determining apneas because they 
are very sensitive to even minor air flow. They are however poor detectors of partial flow 
limitations (hypopneas) because even slight air flow produces large amplitude deflections 
due to their high sensitivity. Apart from thermosensors, nasal pressure can be measured 
by piezoelectric pressure sensors which are very sensitive to hypopneas. Appendix 4 
shows the placement of nasal pressure cannulae104, 105.  
Relevant parameters measured in PSG include total recording time, total sleep 
time, sleep period time, time in bed, sleep efficiency, sleep latency and REM sleep 
latency, and sleep stage distribution. A summary of the entire night’s PSG data can be 
presented in a graphic form called a sleep hypnogram. Appendix 5 shows a sleep 
hypnogram of normal and fragmented sleep patterns105.  
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This study used sleep study data of subjects who underwent home PSG. Apnea-
hypopnea index (AHI) was scored according to the guidelines of the American Academy 
of Sleep Medicine101.  
 
2.2.5 Formation of Advanced Glycation End-products (AGEs) 
AGEs are formed when reducing sugars react non-enzymatically with amino 
groups in proteins, lipids, and nucleic acids. This involves series of reactions in which 
Schiff bases undergo Amadori rearrangement to form the Amadori product. The Amadori 
product undergoes further reactions to generate AGEs. This process is also called the 
Maillard reaction (browning reaction) and was identified in 1912 when it was found that 
a characteristic yellow-brown color was developed when amino acids were heated in the 
presence of reducing sugars41. CML is one of the dominant AGEs and known to be a 
glycoxidation product because it is formed by both oxidation and glycation reactions106. 
CML is also formed as a product of lipid peroxidation42. Glycoxidation and lipoxidation 
reactions are accompanied with reactive oxygen species production; hence CML has been 
characterized as a general biomarker of oxidative stress. A schematic presentation of 
AGE formation pathways is shown in Appendix 6.  
2.2.6 Measurement of CML 
CML was measured as described by Barzilay et al107. Briefly, fasting samples 
were stored at -80 degrees Celsius and CML measured using a competitive enzyme-
linked immunosorbent assay (ELISA); AGE-CML ELISA, Microcoat, Penzberg, 
Germany.  
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2.2.7 Selection and Definition of Covariates 
The following variables were collected for use in this study because previous 
research has shown their association with either sleep disordered breathing (SDB) or 
CML accumulation: age, sex, race, smoking, alcohol intake, BMI, hypertension, diabetes, 
household income, physical activity, general health status, insomnia, estimated 
glomerular filtration rate (eGFR), C-reactive protein, hemoglobin, HDL cholesterol, 
prevalent MI, CHD, stroke, and claudication. Some of these variables were used as 
continuous variables and others were used as categories. Age as a categorical variable 
was classified as 64-69, 70-74, 75-79, and 80 years or more. Race and ethnicity was 
classified as “White”, “African American or Black”, and “other”. The “other” class 
includes American Indian or Alaskan native, Asian or Pacific Islander. BMI was 
categorized according to the World Health Organization guidelines as “normal” (BMI 
<25.0 kg/m2), “overweight” (BMI 25-29.9 kg/m2), or “obese” (BMI ≥30 kg/m2). 
Smoking status was categorized as “nonsmoker”, “former smoker”, or “current smoker”, 
and blood pressure was categorized into “normal”, “prehypertension”, or “hypertension” 
according to the Seventh report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) criteria. 
According to this guideline a normal blood pressure has systolic pressure of less than 120 
mmHg and a diastolic pressure of less than 90 mmHg, prehypertension is systolic blood 
pressure of 120 to 139 mmHg or diastolic pressure of 80 to 89 mmHg, and hypertension 
is systolic pressure of 140 and above or diastolic pressure  of 90 and above. Self-reported 
health status was categorized as “excellent”, “very good”, “good”, “fair”, or “poor” and 
diabetes status was defined based on the American Diabetes Association guidelines. The 
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2-hour glucose test (oral glucose tolerance test-OGTT) was used and diabetes was 
defined as 2 hour blood glucose of greater than or equal to 200 mg/dl, impaired fasting 
glucose (prediabetes) was defined as 2 hour blood glucose of ≥140 to <200 mg/dl, and 
normal was defined as 2 hour blood glucose of less than 140 mg/dl. The status of 
conditions such as MI, CHD, CHF, stroke, Claudication, and insomnia were coded as 
“yes” or “no”, and exercise intensity was categorized as “none”, “low”, “moderate”, or 
high. Household income of participants was put into 5 classes: <$12,000, $12,000-
$24,999, $25,000-$49,999, $50,000-$75,000, and >75,000. 
2.2.8 Inclusion and Exclusion Criteria 
A total of 2287 participants in the CHS have CML records but since the exposure 
of interest is sleep disordered breathing (SDB) assessed by apnea-hypopnea index (AHI), 
we excluded all participants without AHI records. A total of 1285 participants without 
AHI records were excluded leaving a sample size of 1002 that was used in this analysis. 
2.2.9 Statistical Analysis 
CML was measured between 1996 and 1997 (CHS year 9) around the same time 
that polysomnography was conducted on the participants. Linear regression was used to 
test the cross-sectional relationship between SBD (assessed by AHI) and CML 
concentration. CML distribution was skewed to the right and was log transformed before 
analysis. SDB (AHI) was the exposure variable and serum CML concentration was the 
outcome variable. The following were adjusted for: age, sex, race, smoking, alcohol 
intake, BMI, hypertension, estimated glomerular filtration rate (eGFR), C-reactive 
protein, hemoglobin, HDL cholesterol, prevalent MI, CHD, stroke, and claudication. This 
parsimonious set of variables was arrived at through a model building technique 
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recommended originally by Hosmer and Lemeshow108, and described further by 
Jewell109.  It involves examining risk factors in order of their primary interest in terms of 
relationships with the outcome or main predictor, and checking for possible interactions. 
Stratified analyses based on gender and hemoglobin were performed with adjustment for 
the confounders mentioned above. Measurements from previous years were used to 
impute missing values. All analyses were performed using SAS version 9.3. Levels of 
significance of all analyses were based on p-value of 0.05. 
 
2.2.10 Power Calculation (SDB and CML) 
 
2.2.11 Prevalence of sleep apnea in the study population 
More than 18 million adults in America have sleep apnea according to the 
National Sleep Foundation (NSF)110. The NSF also found that individuals ≥40 years are 
at increased risk of sleep apnea. Using the 2010 U.S census111, approximately 124 million 
residents were ≥40 years old. Hence 18 million adults with sleep apnea will amount to 
approximately 15% of the population ≥40 years. The CHS cohort is made up of 
individuals that are ≥65 years of age, and moderate to severe (AHI ≥15) sleep disordered 
breathing was found in 35.2% of the sample. With 1002 participants this results in an 
exposed group of 353 and unexposed group of 649. 
2.2.12 Prevalence of high CML among exposed and unexposed groups 
CML is a metabolic by-product and increased accumulation increases the risk of 
health problems. An investigation into the effect of CML on the risk of hip fracture in the 
CHS showed that all but the first quartile showed increased risk of hip fracture107. This 
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implies the 2nd, 3rd, and 4th quartiles of CML could be regarded as “high” (that is, 75% of 
the population, and in this case ≥65 year olds). In another study the association between 
CML (categorized as “Low” or “High” at the median) and carotid diameter was 
investigated and it was found that “high” CML was associated with enlarged carotid 
diameter112. In this case 50% of the study participants were classified as having “high” 
CML.  
With 95% confidence level, 35.2% prevalence of sleep apnea, 75% “high” CML 
in the study population (unexposed),  and 83% “high” CML in the study population 
(exposed), the power of the study is more than 80% as presented in table 1. 
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Table 1: Power calculation for the association between sleep disordered breathing   
and carboxymethyl-lysine (based on 75% of study population with high CML) 
Power for Cross-Sectional Studies (SDB and CML) 
 Exposed Group Unexposed Group 
 
Sample Size 353 649 
 
Prevalence (or) Coverage (%) 83 75 
   
Power based on:   
Normal approximation 83.04% 
 
Normal approximation with continuity 
correction 
 
80.91% 
 
With 95% confidence level, 35.2% prevalence of sleep apnea, 50% “high” CML 
in the study population (unexposed),  and 59.4% “high” CML in the study population 
(exposed), the power of the study is at least 80% as presented in table 2. 
 
Table 2: Power calculation for the association between sleep disordered breathing 
and carboxymethyl-lysine (based on 50% of study population with high CML) 
Power for Cross-Sectional Studies (SDB and CML) 
 Exposed Group Unexposed Group 
 
Sample Size 353 649 
 
Prevalence (or) Coverage (%) 59.4 50 
   
Power based on:   
Normal approximation 81.4% 
 
Normal approximation with continuity 
correction 
79.54% 
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2.3 RESULTS 
 
A total of 1002 subjects were involved in this study. The mean age was 77.5 and 
28% were 80 years and above [Table 3]. The sample was predominantly Caucasian 
(81%), and made up of 57% females. The mean BMI of participants was 27.2 kg/m2 with 
normal, overweight, and obese subjects forming 31.4%, 46.9%, and 21.7%, respectively.  
Nondrinkers constitute 56.7% of the sample and among drinkers the average alcohol 
consumption per day was 10gm. Non-smokers represent 48.6% of the sample and 6.3% 
of the sample were current smokers. Participants had mean hemoglobin of 13.8 g/dl, and 
by gender it was 13.3 g/dl and 14.4 g/dl for females and males respectively. The mean C-
reactive protein (CRP) concentration was 5.0 mg/L, and the mean estimated glomerular 
filtration rate (eGFR- cystatin C) was 82.4 mL/min/1.73 m2. The percent of sleep time of 
SaO2 below 90% was on average 4.3 among the study participants and about 21 arousals 
were experienced on average per hour of sleep. The mean CML concentration among 
study participants was 6161.2 ng/ml (6.4 ng/ml after log transformation), and participants 
experienced on average 11.5 apneas and hypopneas per hour of sleep. Participants who 
earned $50,000 or more, had moderate to high physical activity, high blood pressure 
(≥140/90), self-reported good health or better, and impaired fasting glucose or diabetic 
formed 16.3%, 53.9%, 52.3%, 83.6%, and 24.4%, respectively, of the sample. 
Participants who had MI, CHD, CHF, stroke, claudication, and insomnia formed 9.8%, 
24.0%, 6.8%, 4.0%, 2.8%, and 18.9%, respectively, of the sample [Table 3].  
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In unadjusted analyses, BMI, % sleep time of SaO2 below 90%, arousal index, 
HDL, and eGFR- cysC, were significantly associated with sleep disordered breathing 
(SDB) measured by Apnea-Hypopnea Index (AHI) [Table 3]. Whilst increasing values of 
BMI, % sleep time of SaO2 below 90%, and arousal index were associated with 
increasing severity of SDB, decreasing values of HDL and eGFR- cysC, were associated 
with increasing severity of SDB. Hemoglobin has a borderline significance with SDB 
(p=0.069) in this unadjusted model and higher levels were associated with increasing 
severity of SDB. Other variables that were significantly associated with SDB in the 
unadjusted model include race/ethnicity, gender, prevalent MI status, and prevalent CHF 
status. African Americans, males, MI patients, and CHF patients were more likely to 
have severe SDB [Table 3]. Variables which significantly influenced CML accumulation 
in the unadjusted models were age, BMI, alcohol use, HDL, triglycerides, hemoglobin, 
eGFR- cysC, arousal index, and smoking status. Higher levels of CML were associated 
with increasing age, and HDL but with decreasing BMI, alcohol use, triglycerides, 
hemoglobin  eGFR- cysC, and arousal index. Current smoking status was significantly 
associated with lower CML levels in the unadjusted analysis [Table 4]. 
Sleep disordered breathing was not associated with CML in either the unadjusted 
or adjusted models [Table 5]. However, modification effects by gender and hemoglobin 
on the association between SDB and CML were identified [Table 6]. The variables in the 
main effects model include apnea-hypopnea index, age, BMI, gender, race, alcohol, 
smoking, stroke, claudication, CHD, MI, diabetes, hypertension, HDL, hemoglobin, 
CRP, and eGFR. As shown in table 4, the model with the 3-way interaction appears to the 
best model for this analysis. Taking the 3-way interaction into consideration, it was found 
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that among males with hemoglobin concentration greater than 14.29 g/dl, there was an 
inverse relationship between SDB and CML concentration, while among females with the 
same hemoglobin level there was a direct relationship between SDB and CML 
concentration [Table 7]. Interaction effects by diabetes and insomnia were investigated 
but were not significant.  
2.3.1 Males with hemoglobin concentration >14.29 g/dl 
Compared to male subjects with no SDB, males with severe SDB have 16.1% 
lower CML concentration if hemoglobin is >14.29 g/dl (p=0.0146). There was no 
significant association between SDB and CML concentration among males with 
hemoglobin ≤14.29 g/dl [Table 7].  
2.3.2 Females with hemoglobin concentration >14.29 g/dl 
Compared to female subjects with no SDB, females with severe SDB have 28.1% 
higher CML concentration if hemoglobin is >14.29 g/dl (p=0.0336). Also, compared to 
female subjects with no SDB, females with mild SDB have 19.0% higher CML 
concentration if hemoglobin is >14.29 g/dl (p=0.0061). There was no significant 
association between SDB and CML concentration among females with hemoglobin 
≤14.29 g/dl [Table 7]. 
2.3.3 The effect of hemoglobin (irrespective of gender) on the SDB-CML association 
Considering the fact that an interaction between SDB (AHI) [Table 6] and 
hemoglobin was detected and that hemoglobin is highly influenced by gender, an 
alternative approach was to find those hemoglobin cut-points where the influence of SDB 
on CML becomes clinically important. This was done by performing analyses with 
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different hemoglobin cut-points until the association between SDB and CML becomes 
significant. The following cut-points have been identified and apply to both males and 
females:  <12.7 g/dl, 12.7 to <14.6 g/dl, and ≥14.6 g/dl.  
 
2.3.4 The effect of hemoglobin <12.7 g/dl (irrespective of gender) on the SDB-CML 
association 
There was no significant association between SDB and CML concentration for 
hemoglobin <12.7 g/dl [Table 8]. 
 
2.3.5 The effect of hemoglobin 12.7-14.59 g/dl (irrespective of gender) on the SDB-
CML association 
Among subjects with hemoglobin concentration between 12.7 and <14.6 g/dl, it 
was found that subjects with severe SDB were more likely (9.1%; p=0.0318) to have 
higher CML concentration compared to subjects with no SDB. It was also found within 
the same hemoglobin class that subjects with mild SDB were more likely (5.9%; 
p=0.0223) to have higher CML concentration compared to subjects with no SDB [Table 
8]. 
2.3.6 The effect of hemoglobin ≥14.6 g/dl (irrespective of gender) on the SDB-CML 
association 
Among subjects with hemoglobin concentration ≥14.6 g/dl, it was found that 
subjects with severe SDB have significantly lower CML concentration (13.8%; 
p=0.0364) compared to subjects with no SDB [Table 8]. 
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2.4 DISCUSSION  
The multivariable models did not detect significant association between sleep 
disordered breathing (SDB) and carboxymethyl-lysine (CML) concentration.  It was 
found however that the association between SDB and CML was modified by gender and 
hemoglobin. At high hemoglobin levels females with SDB have higher levels of CML 
whilst males with SDB have lower levels of CML. This study is the first of its kind with 
no previous studies to compare the findings to. However, a few studies investigated the 
association between SDB and advanced glycation end-products broadly.  
In one study conducted by Lam et al.,96 among 105 males (mean age 43.5 years) 
without diabetes, significantly higher serum advanced glycation end-product (AGE) 
levels were observed in subjects with SDB (AHI ≥5), compared to subjects without SDB 
(AHI <5). They also found that among subjects with moderate to severe SDB who 
underwent CPAP treatment, serum levels of advanced glycation end-products were 
decreased indicating a direct relationship between SDB and advanced glycation end-
products. This is contrary to the lower CML concentration in severe SDB found among 
males with high hemoglobin in our study.  The difference in findings could arise from the 
differences between CML (a specific AGE) and AGEs in general. In addition, we 
stratified on hemoglobin but Lam et al. did not. Furthermore, Lam et al. studied a 
younger population (mean age: 43.5 years) while we studied a much older population 
(mean age: 77.5 years) which could potentially contribute to differences in the findings.  
Tan et al.97 investigated the association between SDB and advanced glycation 
end-products in a case-control study involving 119 nondiabetic patients with SDB and 
234 age-matched healthy controls. They found that markers of oxidative stress increased 
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in SDB patients and serum levels of advanced glycation end-products increased. The 
studies by Tan et al., and Lam et al. were consistent in establishing a direct relationship 
between SDB and advanced glycation end-products. We found a direct relationship 
among females but not males, and only after hemoglobin stratification. CML is a well 
characterized advanced glycation end-product, and has been described as the general 
biomarker of oxidative stress. Hence a direct relationship between SDB and CML is 
expected but our data only partially supports that hypothesis. 
2.4.1 Mechanisms linking sleep disordered breathing to CML concentration 
Revisiting our hypothesis of free radical production thorough the xanthine oxidase 
pathway and how that might affect CML accumulation, it has been established that SDB 
is characterized by intermittent hypoxia and re-oxygenation after each hypoxic episode 
generates free radicals. Overproduction of free radicals leads to a state of oxidative stress 
and could accelerate CML production. The modification effect by gender is plausible 
because in premenopausal women estrogen is very active in scavenging free radicals, and 
also has the ability to stimulate enzymes to detoxify free radicals. This implies that in 
premenopausal women, one could expect reduced CML accumulation compared to males 
even in sleep disordered breathing situations. In this study the mean age was 73.5 years 
with minimum of 64 years and a maximum of 95 years. Therefore the women in this 
study are all postmenopausal and unless they all use estrogen replacement therapies, one 
should not expect the protective effect of estrogen on free radicals among women in this 
study. Significant effects of SDB on CML concentration was found but only at high 
hemoglobin levels and these effects differ by gender. Among females with hemoglobin 
concentration >14.29 g/dl, increased CML concentration was associated with mild and 
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severe SDB [Table 7] and this supports our hypothesis that increased free radical 
production in SDB could lead to increased CML accumulation; this was not the case for 
males. Focusing more on this result among females, what could be the possible reasons 
why the effect of SDB on CML was only significant at the higher spectrum of 
hemoglobin?  
Circulating ferrous hemoglobin participates in chemical reactions that could be 
toxic in living organisms. Among these reactions is autoxidation of oxy-hemoglobin. 
Oxy-hemoglobin undergoes a slow, but spontaneous intramolecular redox reaction, in 
which the heme iron is oxidized to the ferric form and oxygen reduced to superoxide113-
116:  
 
Hb2+O2   →   Hb3+  +  O2•- 
  
In the presence of adequate antioxidant defense systems, the superoxide will be 
dismutated to oxygen and hydrogen peroxide by superoxide dismutase: 
 
2O2•-   + 2H+ → O2 + H2O2 
In the absence of antioxidant enzymes these reactions could promote hydroxyl radical 
formation via the following reactions26: 
Fenton reaction: Fe2+ + H2O2 → Fe3+ + OH• + OH- or the 
Haber–Weiss mechanism: O2•- + H2O2 → OH• + OH- + O2; catalyzed by Fe3+ 
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Intermittent hypoxia followed by re-oxygenation which occurs in sleep disordered 
breathing (SDB) generates superoxide28, 29 and hemoglobin serves as the source of iron 
which catalyzes the reactions leading to the more potent hydroxyl radical113. CML is a 
biomarker of oxidative stress and accelerated CML production as a result of increased 
free radicals at high hemoglobin levels is plausible. The increased CML production at 
high hemoglobin levels occurred mainly in females and not in males because in 
postmenopausal women (as in this study), iron stores tend to increase rather than decrease 
(Appendix 7)117. Ferritin, an intracellular protein that stores iron and controls its release 
has been found to increase whiles estrogen decrease during the menopausal transition 
(Appendix 8)118.  
The increase in body iron in females after menopause has oxidative burden 
consequences. This is because menopause is accompanied with increase in body weight, 
decreased antioxidant defenses and chronic inflammation119. This results in increased free 
radical production and reduced antioxidant defenses in postmenopausal women, a 
situation of oxidative stress. Oxidative stress from increased free radicals in SDB at high 
hemoglobin levels in postmenopausal women is a plausible cause of the increased CML 
concentration found in these individuals. A schematic presentation of iron increase during 
menopause and oxidative stress is shown in Appendix 9.  
Among males SDB was significantly inversely associated with CML 
concentration at hemoglobin >14.29. In other words SDB (severe) was found to be 
associated with lower CML concentration. This is the first study examining the 
relationship between SDB and CML hence there are no comparative studies for this 
observation. However, there are plausible explanations for this association. Males have 
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higher hemoglobin concentration than females and are expected to generate more reactive 
oxygen species in the presence of SDB and hence increased CML accumulation. 
However, the reverse was observed and may partly be due to unmeasured 
carboxyhemoglobin (COHb) in males. Cigarette smoking raises the blood levels of 
COHb resulting in reduced hemoglobin which interrupts oxygen transport from the lungs 
to the rest of the body120. Hence unlike females whose iron stores increase after 
menopause, older males are more likely to be anemic due to tobacco use and that could 
influence the effect of hemoglobin on the SDB and CML association. Results from this 
study have shown that males were significantly likely than females to be smokers (p 
<.0001) [Figure 2] which adds evidence to the COHb hypothesis.  
Figure 2: Percent of males and females in each smoking category 
 
Apart from the hindrance of hemoglobin function by COHb, older males could 
actually suffer reduced hemoglobin due to colorectal cancer121, 122.  An estimated 71,830 
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men and 65,000 women will be diagnosed with colorectal cancer and 26,270 men and 
24,040 women will die of the disease in 2014, according to the National Center for 
Health Statistics123. Females can build up their iron stores after menopause but males 
cannot and the associated iron deficiency in males could play an important role in 
reducing oxidative stress and hence the observed lower CML concentration with SDB124.  
Physical activity has been found in many studies to protect against oxidative 
stress, especially in older individuals and could also account for the association between 
SDB and CML concentration in males with hemoglobin >14.29g/dl. A study by 
Traustadóttir et al.,125 tested the hypothesis that physically fit older adults would have 
less oxidative stress than unfit age-matched controls. They recruited 37 fit individuals 
with an average age of 65 years, and 35 unfit individuals with an average age of 67.7 
years, and found that fit individuals had significantly lower oxidative stress markers 
compared to the unfit individuals. Our results have shown that males were more likely 
than females to engage in moderate to high physical activity (p=0.0028), as shown on 
figure 3. More specifically, it was found that males with hemoglobin above 14.29 g/dl 
were significantly more likely than females in the same hemoglobin group, to engage in 
moderate to high physical activity (p=0.0391), as shown on figure 4. These findings 
might explain the protective effect of SDB on CML concentration found among males 
with hemoglobin >14.29 g/dl.  
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Figure 3: Percent of males and females in each exercise intensity category 
 
Figure 4: Percent of males and females by exercise intensity: hemoglobin >14.29 g/dl 
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These findings are also consistent with findings by Karolkiewicz et al.,126 who 
studied the relationship between markers of oxidative stress and physical activity among 
men (mean age: 73.4 years). They found that compared with less active men, more active 
men have higher plasma levels of glutathione (GSH), indicating favored antioxidant 
potential, and lower thiobarbituric acid reactive substance (TBARS) concentration, 
indicating inhibited lipid peroxidation. Pierce et al.,127 also came to the conclusion that 
physical activity protects against the harmful effects of oxidative stress when they 
compared older men who perform habitual aerobic exercise with their sedentary 
counterparts.  
The lower CML concentration found among males with severe SDB at high 
hemoglobin levels may not necessarily be a protective effect of severe SDB. Life 
expectancy for males and females in the United States is approximately 77 and 82 years, 
respectively, and we studied a population with mean age of 77.5 years. It is likely that 
males with severe SDB and who by our hypothesis should have high CML levels have 
died before CML was measured for this analysis. Hence we may be looking at males who 
even with SDB have survived for reasons beyond the scope of this study, and their CML 
values may not be reflective of what would be observed if a younger population were 
studied.   
2.4.2 The effect of hemoglobin on the association between SDB and CML  
The 3-way interaction between gender, hemoglobin, and SDB on the CML 
concentration has been discussed above. However in table 7 we sought to find 
hemoglobin levels at which the effect of SDB on CML concentration would be clinically 
important. New hemoglobin cut-points have been created for the entire sample without 
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gender stratification. Mild and severe SDB were significantly associated with higher 
CML concentrations in the normal hemoglobin class (12.7-14.59 g/dl). This normal 
hemoglobin class involved more than half of the entire study sample and divided among 
males and females as 37% and 63%, respectively. Although this hemoglobin level 
appears to be important clinically in terms of CML accumulation and consistent with our 
hypothesis, the unequal representation of gender raised concerns. This is because female 
gender has been associated with increased CML concentration in the presence of SDB (at 
hemoglobin >14.29 g/dl) [Table 6] and since females have dominated this normal 
hemoglobin class (63%), it is likely that the association observed in this hemoglobin class 
is due to female gender. In the high hemoglobin class (≥14.6 g/dl) [Table 8] severe SDB 
was associated with lower CML concentration. This high hemoglobin class was made up 
of 77.6% males. It is also likely that male gender influenced the direction of the 
association between SDB and CML concentration. Nevertheless, these results further 
strengthen the importance of the gender effect observed in table 7. The hemoglobin 
cutpoints in table 6 will need to be tested with a much larger sample such that each class 
has adequate representation of males and females. If significant associations disappear 
after equal representation of gender in the hemoglobin classes, then the 3-way interaction 
between gender, hemoglobin, and SDB (as done in table 7) will be the best approach for a 
study examining the relationship between SDB and CML concentration. 
2.4.3 Strengths and Limitations  
Strengths of this paper include firstly, the reliability of the data. This study was 
conducted in the cardiovascular health study (CHS) initiated by the National Heart, Lung 
and Blood Institute, and has extensive clinical data with participants coming from four 
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U.S communities. More than 1000 research papers have been published in peer reviewed 
journals since the cohort began giving credibility to the dataset and hence our findings. 
Secondly, our findings support the hypothesis that oxidative stress from SDB affects 
CML accumulation. Although the association between SDB and CML has not been 
studied, our findings are consistent with studies that investigated the effects of factors 
like smoking, physical activity, and hemoglobin on oxidative stress. Limitations of this 
study include its cross-sectional nature. Ethical reasons will not allow for a prospective 
study between SDB and CML concentration since SDB can be treated. However, a 
second or more CML measurements with time may help to retrospectively study 
longitudinal effects of SDB on CML accumulation. This study included only subjects 
with AHI records limiting our sample size to 1002. A larger sample may be instrumental 
in establishing the validity of the findings. Lastly, there are no studies on the association 
between SDB and CML for comparison. Availability of such a study could provide some 
useful clues on the best modelling approach for the association. Nevertheless, the 
approaches used in this study are consistent with published literature and would pave the 
way for future researchers.  
2.4.4 Recommendations for Future Research  
Future studies would be needed to further investigate the inverse relationship 
between SDB and CML accumulation that was observed at high hemoglobin levels 
among males. A larger sample size will be useful to confirm such an association. Also, it 
will be important to measure carboxyhemoglobin in males to verify if the interaction 
between hemoglobin and SDB persists and if SDB protects against increased CML 
concentration as was observed in this study at high hemoglobin levels. Lastly, future 
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studies to test the association between SDB and CML concentration at hemoglobin levels 
of <12.7 g/dl, 12.7-14.29 g/dl, and >14.29 g/dl, will be important in establishing the role 
of gender in the association between SDB and CML concentration. 
2.5 CONCLUSION 
CML levels have been linked to disease, particularly cardiovascular disease. 
Findings from this study have indicated that CML level depends on a complex interplay 
of factors such as gender, hemoglobin, and sleep disordered breathing. Sleep disordered 
breathing is characterized by production of free radicals and hemoglobin serves as the 
source of iron that catalyzes the reactions resulting in the increased CML concentration 
found at high hemoglobin levels. The protective effect of SDB found among males could 
be attributed to physical activity which is common among older men resulting in reduced 
oxidative stress and hence lower CML. Cigarette smoking among males has also been 
hypothesized to reduce oxidative stress because more carboxyhemoglobin is produced 
inhibiting the reactions of hemoglobin in promoting free radicals. These findings have 
public health implications because SDB can be treated and antioxidant defenses systems 
can be upregulated through physical activity to lower CML accumulation and hence 
reduce diseases that arise from oxidative damage.    
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Table 3: Characteristics of up to 1002 participants from the Cardiovascular Health Study 
by severity of SDB 
  AHI  
Variable        N Normal 
N=396 
Mild 
N=353 
Moderate 
N=162 
Severe 
N=91 
F (P-value) 
F (P-value) 
Age (years),  mean (s.d) 1002 77.2 (4.4) 77.7 (4.5) 77.7 (4.3) 77.8 (4.9) 2.3 (0.1318) 
BMI (kg/m2) 990 26.7 (4.3) 27.2 (4.2) 27.9 (4.2) 28.7 (5.5) 20.3 (<.0001) 
Alcohol (GM) 988 3.4 (6.6) 5.2 (11.4) 4.6 (10.9) 4.5 (11.7) 2.5 (0.1159) 
Cholesterol(mg/dl) 968 203 (36.5) 200 (41.0) 202 (40.9) 193.4(37.5) 3.0 (0.0843) 
Adjusted LDL (mg/dl) 963 128 (34.1) 127 ( 34.4) 130 (29.9) 129.4(28.4) 0.4 (0.5504) 
HDL (mg/dl) 982 55.1 (15.2) 53.2 (13.9) 51.2 (13.9) 51.1 (12.3) 10.9 (0.0010) 
Triglyceride (mg/dl) 985 141 (79.8) 147 (100) 149 (88.1) 139.0(99.1) 0.11 (0.7401) 
Hemoglobin (g/dl) 978 13.7(1.4) 13.7 (1.4) 13.9 (1.3) 14.0 (1.2) 3.3 (0.0686) 
C-reactive protein (mg/L) 972 5.2 (9.9) 4.6 (8.9) 5.7 (10.2) 4.1 (4.6) 0.2 (0.6381) 
eGFR-cysC 925 83.6(19.0) 83.7 (18.8) 78.0 (17.3) 79.4 (16.6) 8.7 (0.0033) 
% Sleep time SaO2  < 90% 1002 1.8 (8.3) 3.8 (11.6) 6.7 (12.6) 13.3 (15.8) 79.7 (<.0001) 
Arousal index all 959 17.2 (9.3) 19.2 (8.8) 25.0 (11.3) 36.5 (15.1) 235.1(<.0001
)        
Age                        N (%)      X2 (P-value) 
<75 263 114 (28.8) 88 (24.9) 41 (25.3) 20 (22.0)  
75-79 455 174 (43.9) 160 (45.3) 75 (46.3) 46 (50.6)  
≥80 284 108 (27.3) 105 (29.8) 46 (28.4) 25 (27.5) 3.07 (0.8001) 
       
Gender       
Male 429 130 (32.8) 157 (44.5) 85 (52.5) 57 (62.6)  
Female 573 266 (67.2) 196 (55.5) 77 (47.5) 34 (37.4) 37.3 (<.0001) 
       
Race       
White 816 313 (79.0) 294 (83.3) 141 (87.0) 68 (74.7)  
Black/AA 179 82 (20.7) 56 (15.9) 20 (12.4) 21 (23.1)  
Other 7 1 (0.3) 3 (0.8) 1 (0.6) 2 (2.2) 0.0330* 
       
BMI (kg/m2)       
Normal 311 147 (37.5) 101 (29.2) 41 (25.5) 22 (24.2)  
Overweight 464 175 (44.6) 173 (50.0) 78 (48.5) 38 (41.7)  
Obese 215 70 (17.9) 72 (20.8) 42 (26.0) 31 (34.1) 20.9 (0.0019) 
       
Smoking Status       
Non-smoker 485 196 (49.5) 162 (46.4) 85 (52.5) 42 (46.7)  
Former smoker 449 169 (42.7) 170 (48.7) 71 (43.8) 39 (43.3)  
Current smoker 63 31 (7.8) 17 (4.9) 6 (3.7) 9 (10.0) 8.9 (0.1799) 
       
Income       
<12,000 168 68 (18.0) 63 (18.8) 21 (13.8) 16 (19.3)  
12,000 - <25,000 333 145 (38.4) 98 (29.2) 61 (40.1) 29 (34.9)  
25,000 - <50,000 293 112 (29.6) 104 (30.9) 50 (32.8) 27 (32.5)  
50,000  -  75,000 89 28 (7.4) 45 (13.4) 9 (5.9) 7 (8.4)  
>75,000 66 25 (6.6) 26 (7.7) 11 (7.2) 4 (4.8) 18.0 (0.1159) 
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Table 3: Characteristics of up to 1002 participants from the Cardiovascular Health Study 
by severity of SDB (Continued)  
  AHI  
Variable        N Normal 
N=396 
Mild 
N=353 
Moderate 
N=162 
Severe 
N=91 
X2 (P-value) 
X2 (P-value) 
Exercise Intensity       
No Exercise 71 25 ( .3) 32 (9.2) 7 (4.4) 7 (7.7)  
Low 388 149 (37.7) 148 (42.5) 57 (35.4) 34 (37.4)  
Moderate 393 161 (40.8) 122 (35.1) 71 (44.1) 39 (42.9)  
High 143 60 (15.2) 46 (13.2) 26 (16.2) 11 (12.1) 10.3 (0.3263) 
       
Blood Pressure Status       
Normal 351 140 (35.5) 126 (35.8) 56 (34.6) 29 (31.9)  
Prehypertension 126 50 (12.7) 48 (13.6) 15 (9.3) 13 (14.3)  
Hypertension 522 204 (51.8) 178 (50.6) 91 (56.2) 49 (53.9) 3.0 (0.8060) 
       
General Health Status       
Excellent 44 19 (4.8) 19 (5.4) 3 (1.9) 3 (3.3)  
Very Good 315 123 (31.1) 109 (31.0) 62 (38.3) 21 (23.1)  
Good 477 194 (49.0) 166 (47.3) 71 (43.8) 46 (50.5)  
Fair  153 56 (14.1) 56 (16.0 23 (14.2) 18 (19.8)  
Poor 11 4 (1.0 1 (0.3) 3 (1.8) 3 (3.3) 17.6 (0.1279) 
       
MI Status       
No 904 370 (93.4) 314 (89.0) 141 (87.0) 79 (86.8)  
Yes 98 26 (6.6) 39 (11.0 21 (13.0) 12 (13.2) 8.3 (0.0395) 
CHD       
No 761 317 (80.0) 262 (74.2) 117 (72.2) 65 (71.4)  
Yes 241 79 (20.0) 91 (25.8) 45 (27.8) 26 (28.6) 6.5 (0.0907) 
CHF       
No 934 375 (94.7) 327 (92.6) 153 (94.4) 79 (86.8)  
Yes 68 21 (5.30) 26 (7.4) 9 (5.6) 12 (13.2) 7.8 (0.0493) 
Stroke       
No 962 380 (96.0) 339 (96.0) 158 (97.5) 85 (93.4)  
Yes 40 16 (4.0) 14 (4.0) 4 (2.5) 6 (6.6) 0.4592* 
Claudication       
No 974 386 (97.5) 346 (98.0) 154 (95.1) 88 (96.7)  
Yes 28 10 (2.5) 7 (2.0) 8 (4.9) 3 (3.3) 0.2724* 
       
Diabetes Status (ADA)       
Normal 754 316 (80.2) 260 (74.1) 111 (68.9) 67 (73.6)  
IFG 112 38 (9.6) 43 (12.2) 20 (12.4) 11 (12.1)  
Diabetic 131 40 (10.2) 48 (13.7) 30 (18.6) 13 (14.3) 10.2 (0.1159) 
       
Insomnia       
No 797 310 (80.3) 275 (79.3) 133 (83.1) 79 (87.8)  
Yes 186 76 (19.7) 72 (20.7) 27 (16.9) 11 (12.2) 4.0 (0.2643) 
AHI CUTPOINTS (events/hr of sleep): Normal (<5); Mild (5 to <15); Moderate (15 to 30); Severe (>30)               
*P-value from Fisher’s Exact Test.    
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Table 4: Characteristics of up to 1002 participants from the Cardiovascular Health Study 
by quartiles of CML 
  CML  
Variable        N Quartile 1 
N=251 
Quartile 2 
N=250 
Quartile 3 
N=250 
Quartile 4 
N=251 
F (P-value) 
F (P-value) 
Age (years),        mean (s.d) 1002 76.3 (3.8) 77.5 (4.4) 77.9 (4.5) 78.4 (4.8) 29.2(<.0001
) BMI (kg/m2) 990 28.  (4.5) 27.  (4.5) 26.  (4.2) 26.4 (4.2) 35.7(<.0001
) Alcohol (GM) 988 5.5 (12.1) 4.5 (8.5) 3.3 (8.4) 4.0 (9.4) 4.6 (0.0327) 
Cholesterol (mg/dl) 968 205 (39.0) 200 (35.6) 199 (37.4) 200 (43.5) 2.2 (0.1426) 
Adjusted LDL (mg/dl) 963 129 (34.1) 127 (33.0) 128 (31.8) 128 (33.5) 0.12(0.7262) 
HDL (mg/dl) 982 52.1 (13.8) 52.6 (13.5) 53.3 (14.4) 55.7 (15.5) 8.0 (0.0047) 
Triglyceride (mg/dl) 985 157 (78.5) 140 (74.6) 143 (103.0) 136 (100.7) 5.9 (0.0151) 
Hemoglobin (g/dl) 978 14.0 (1.2) 13.9 (1.4) 13.8 (1.2) 13.5 (1.5) 19.3(<.0001
) C-reactive protein (mg/L) 972 4.6 (5.0) 5.3 (10.9) 5.9 (12.9) 4.2 (5.6) 0.1 (0.8282) 
eGFR-cysC 925 84.9 (17.3) 82.6 (17.9) 81.4 (18.5) 80.5 (20.3) 7.0 (0.0081) 
% Sleep time of SaO2 < 90% 1002 4.7 (10.9) 4.3 (11.2) 4.7 (12.5) 3.7 (11.5) 0.8 (0.3855) 
Arousal index all 959 21.9 (13.2) 21.3 (11.2) 20.2 (10.2) 20.1 (11.0) 4.0 (0.0473) 
       
Age                            N (%)      X2 (P-value) 
<75 263 84 (33.5) 62 (24.8) 62 (24.8) 55 (21.9)  
75-79 455 121 (48.2) 118 (47.2) 109 (43.6) 107 (42.6)  
≥80 284 46 (18.3) 70 (28.0) 79 (31.6) 89 (35.5) 22.7(0.0009) 
       
Gender       
Male 429 96 (38.3) 113 (45.2) 115 (46.0) 105 (41.8)  
Female 573 155 (61.7) 137 (54.8) 135 (54.0) 146 (58.2) 3.9 (0.2776) 
       
Race       
White 816 209 (83.3) 199 (79.6) 208 (83.2) 200 (79.7)  
Black/AA 179 41 (16.3) 49 (19.6) 39 (15.6) 50 (19.9)  
Other 7 1 (0.4) 2 (0.8) 3 (1.2) 1 (0.4) 0.6931* 
       
BMI (kg/m2)       
Normal 311 42 (16.9) 76 (30.9) 97 (39.3) 96 (38.5)  
Overweight 464 139 (56.1) 111 (45.1) 105 (42.5) 109 (43.8)  
Obese 215 67 (27.0) 59 (24.0) 45 (18.2) 44 (17.7) 37.3(<.0001
)        
Smoking Status       
Non-smoker 485 110 (44.0) 104 (41.9) 134 (53.8) 137 (54.8)  
Former smoker 449 116 (46.4) 128 (51.6) 98 (39.4) 107 (42.8)  
Current smoker 63 24 (9.6) 16 (6.5) 17 (6.8) 6 (2.4) 21.7 (0.0014 
       
Income       
<12,000 168 49 (20.6) 40 (17.3) 34 (14.1) 45 (18.8)  
12,000 - <25,000 333 84 (35.3) 73 (31.6) 94 (39.0) 82 (34.3)  
25,000 - <50,000 293 70 (29.4) 77 (33.3) 75 (31.1 ) 71 (29.7)  
50,000  -  75,000 89 23 (9.7) 22 (9.5) 22 (9.1) 22 (9.2)  
>75,000 66 12 (5.0) 19 (8.2) 16 (6.6) 19 (8.0) 7.9 (0.7924) 
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Table 4: Characteristics of up to 1002 participants from the Cardiovascular Health Study 
by quartiles of CML (cont’d) 
  CML  
Variable        N Quartile 1 
N=251 
Quartile 2 
N=250 
Quartile 3 
N=250 
Quartile 4 
N=251 
X2 (P-value) 
X2 (P-value) 
Exercise Intensity       
No Exercise 71 24 (9.6) 18 (7.3) 16 (6.4) 13 (5.2)  
Low 388 94 (37.8) 101 (40.9) 94 (37.8) 99 (39.6)  
Moderate 393 98 (39.4) 91 (36.8) 100 (40.2) 104 (41.6)  
High 143 33 (13.3 37 (15.0) 39 (15.6 34 (13.6) 5.6 (0.7836) 
       
Blood Pressure Status       
Normal 351 88 (35.3) 97 (38.8) 88 (35.3) 78 (31.1)  
Prehypertension 126 38 (15.3) 30 (12.0) 31 (12.5) 27 (10.8)  
Hypertension 522 123 (49.4) 123 (49.2) 130 (52.2) 146 (58.2) 6.8 (.3394) 
       
General Health Status       
Excellent 44 13 (5.2) 8 (3.2) 16 (6.4) 7 (2.8)  
Very Good 315 80 (31.9) 84 (33.7) 74 (29.7) 77 (30.7)  
Good 477 121 (48.2) 112 (45.0) 122 (49.0) 122 (48.6)  
Fair  153 35 (13.9) 43 (17.3) 35 (14.1) 40 (15.9)  
Poor 11 2 (0.8) 2 (0.8) 2 (0.8) 5 (2.0) 9.7 (0.6280) 
       
MI Status       
No 904 225 (89.6) 227 (90.8) 229 (91.6) 223 (88.8)  
Yes 98 26 (10.4) 23 (9.2) 21 (8.4) 28 (11.2) 1.3 (0.7367) 
CHD       
No 761 196 (78.1) 193 (77.2) 190 (76.0) 182 (72.5)  
Yes 241 55 (21.9) 57 (22.8) 60 (24.0) 69 (27.5) 2.5 (0.4811 
CHF       
No 934 238 (94.8) 235 (94.0) 231 (92.4) 230 (91.6)  
Yes 68 13 (5.2) 15 (6.0) 19 (7.6) 21 (8.4) 2.5 (0.4714) 
Stroke       
No 962 244 (97.2) 238 (95.2) 239 (95.6) 241 (96.0)  
Yes 40 7 (2.8) 12 (4.8) 11 (4.4) 10 (4.0) 1.5 (0.6863) 
Claudication       
No 974 243 (96.8) 244 (97.6) 247 (98.8) 240 (95.6)  
Yes 28 8 (3.2) 6 (2.4) 3 (1.2) 11 (4.4) 5.0 (0.1751) 
       
Diabetes status (ADA)       
Normal 754 174 (69.3) 183 (73.5) 197 (79.8) 200 (80.0)  
IFG 112 34 (13.6) 32 (12.9) 25 (10.1) 21 (8.4)  
Diabetic 131 43 (17.1) 34 (13.7) 25 (10.1) 29 (11.6) 11.7(0.0678) 
       
Insomnia       
No 797 194 (79.8) 194 (79.5) 201 (81.7) 208 (83.2)  
Yes 186 49 (20.2) 50 (20.5) 45 (18.3) 42 (16.8) 1.4 (0.6976) 
LOG(CML) Quartiles (ng/ml): (1) ≤6.1972;  (2) >6.1972-6.3599;  (3) 6.3599-6.5341; (4) >6.5341                         
*P-value from Fisher’s Exact Test;   
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Table 5: The effect of SDB (AHI) on CML (N=1002) 
Parameter N Estimate Standard Error t Value Pr >|t| 
AHI (events/hr): 
Model 1 
 -0.0003 0.0007 -0.32 0.7218 
AHI (events/hr): 
Model 2 
 -0.0004 0.0008 -0.56 0.5770 
      
SDB Severity: Model 1      
Normal 396 Referent    
Mild 353 0.0209 0.0205 1.02 0.3080 
Moderate 162 0.0040 0.0260 0.15 0.8769 
Severe 91 0.0089 0.0325 0.27 0.7842 
      
SDB Severity: Model 2      
Normal 396 Referent    
Mild 353 0.0314 0.0214 1.47 0.1425 
Moderate 162 0.0040 0.0275 0.15 0.8842 
Severe 91 0.0004 0.0348 0.01 0.9915 
Model 1 was unadjusted; Model 2 adjusted for age, gender, BMI, smoking, alcohol, HDL, C-reactive 
protein, hemoglobin, eGFR-Cystatin C, CHD, MI, Claudication, Stroke, diabetes, hypertension, race. 
 
 
Table 6: Interaction checks and model selection 
Model # Model DF LR P-
value 
Comments 
1 Main Effects (No interaction) 24 319.4 -  
2 A*H 27 333.1 0.0033 b/n model 2 & 1 
3 A*G 27 327.1 0.0526 b/n 3 & 1 
4 H*G 25 324.9 0.0190 b/n 4 & 1 
5 (A*H) (A*G) 28 339.2 0.0135 b/n 5 & 2 
6 (A*H) (A*G) (H*G) 29 344.6 0.0201 b/n 6 & 5 
7 (A*H) (A*G) (H*G) (A*H*G) 32 354.2 0.0223 b/n 7 & 6 
A=Apnea-Hypopnea Index;   H=Hemoglobin;   G=Gender 
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Table 7: The effect of SDB (AHI) on CML stratified by GENDER and HEMOGLOBIN 
concentration 
 HEMOGLOBIN 
 <13.20 13.20 – 14.29 >14.29 
 N β P-value N β P-value N β P-value 
ALL (N=978)          
SDB Severity:          
Normal (n=389) 138 Ref  132 Ref  119 Ref  
Mild (n=340) 111 0.049 0.261 124 0.037 0.220 105 0.016 0.676 
Moderate(n=158) 43 0.021 0.723 58 0.033 0.387 57 -0.039 0.401 
Severe (n=91) 24 0.054 0.484 31 0.026 0.619 36 -0.062 0.271 
          
MALES (N=423)          
SDB Severity:          
Normal (n=129) 23 Ref  40 Ref  66 Ref  
Mild (n=154) 19 -0.082 0.588 51 0.068 0.166 84 -0.067 0.166 
Moderate (n=83) 8 -0.075 0.679 31 0.104 0.086 44 -0.084 0.152 
Severe (n=57) 8 0.010 0.962 18 0.038 0.606 31 -0.161 0.0146 
          
FEMALES (N=555)          
SDB Severity:          
Normal (n=260) 115 Ref  92 Ref  53 Ref  
Mild (n=186) 92 0.055 0.249 73 0.041 0.328 21 0.189 0.0061 
Moderate (n=75) 35 0.023 0.729 27 -0.009 0.864 13 0.050 0.553 
Severe (n=34) 16 0.063 0.480 13 -0.013 0.877 5 0.281 0.0336 
Models were adjusted for age, BMI, smoking, alcohol, HDL, C-reactive protein, eGFR-Cystatin C, CHD, 
MI, Claudication, Stroke, diabetes, hypertension, race.  
Ref=Referent 
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Table 8: The effect of SDB (AHI) on CML by HEMOGLOBIN concentration 
Parameter N Estimate Standard Error t Value Pr >|t| 
      
HEMOGLOBIN CLASS 1 (<12.7 g/dl) 185     
SDB Severity:      
Normal 78 Referent    
Mild 67 0.029 0.058 0.51 0.614 
Moderate 28 0.009 0.076 0.12 0.903 
Severe 12 0.019 0.108 0.18 0.858 
      
HEMOGLOBIN CLASS 2 (12.7 – 14.59) 552     
SDB Severity:      
Normal 221 Referent    
Mild 195 0.0591 0.026 2.29 0.0223 
Moderate 83 0.030 0.034 0.89 0.376 
Severe 53 0.0909 0.042 2.15 0.0318 
      
HEMOGLOBIN CLASS 3 (≥14.6 g/dl) 241     
SDB Severity:      
Normal 90 Referent    
Mild 78 -0.025 0.043 -0.57 0.569 
Moderate 47 -0.039 0.053 -0.74 0.458 
Severe 26 -0.1381 0.065 -2.11 0.0364 
Models were adjusted for age, BMI, gender, smoking, alcohol, HDL, C-reactive protein, eGFR-Cystatin C, 
CHD, MI, Claudication, Stroke, diabetes, hypertension, race. 
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CHAPTER THREE 
THE JOINT EFFECT OF OBESITY AND SLEEP INADEQUACY ON RISK OF 
TYPE-2 DIABETES 
 
3.1 INTRODUCTION 
Diabetes is the seventh leading cause of death in the US affecting 25.8 million 
people (8.3% of the U.S population)128 . It is a major risk factor for hypertension, heart 
disease and stroke. Co-morbid effects of diabetes include kidney disease, blindness, 
nervous system damage, and too commonly nontraumatic lower-limb amputation. 
Several epidemiological studies have indicated an association between poor patterns of 
sleep and diabetes risk but the results have not been conclusive129-134.  Moreover, sleep 
duration and sleep quality have often been analyzed separately in both longitudinal and 
cross-sectional studies, and only very few studies have incorporated aspects of both sleep 
duration and quality into their analyses135, 136.  Sleep duration is measured by the number 
of hours a person sleeps in a day, and does not take into account the nature of the sleep. 
Sleep quality on the other hand describes the total sleep pattern of an individual.  Major 
factors deleterious to sleep quality include sleep apnea, anxiety (depression), insomnia, 
snoring, and medical conditions such as COPD, heartburn, lung problems, chronic pain, 
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and enlarged prostate137-140.  These factors can lead to difficulty either in initiating sleep 
or in maintaining sleep141, 142. 
Obesity plays an important role in the association between sleep and diabetes. 
Obesity prevalence is known to be higher among those with short sleep duration143-146, 
and obesity is also known to elevate the risk of diabetes147, 148. Sleep problems such as 
obstructive sleep apnea (OSA) and snoring have also been found to increase the risk of 
diabetes independent of obesity149, making it unclear what role obesity plays in the 
association between sleep and diabetes. Previous studies have generally adjusted for 
obesity or BMI but have not specifically investigated the potential complex role obesity 
plays in the relationship between sleep insufficiency and diabetes129, 134, 150. It is possible 
that associations between sleep and diabetes are modified or confounded by obesity.  
Furthermore, sleep disorders, obesity, and diabetes are all entangled in web of 
oxidative stress. It is however not clear whether it is the oxidative stress from sleep-
disordered breathing that contributes to the development of diabetes, or if sleep problems 
are the results of diabetes. The association gets even more complicated in the presence of 
obesity. This study investigates the joint effect of sleep and obesity on the risk of diabetes 
with the aim of identifying relationships that may be useful in explaining some of the 
complication and provide basis for sound public health practice. 
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3.1.1 Objectives 
1. To investigate the association between sleep and diabetes using sleep quantity and 
quality measures 
2. To investigate the effect of possible interaction between sleep quantity and sleep 
quality on the diabetes 
3. To investigate the joint effect of sleep and obesity on the risk of diabetes 
 
3.1.2 Hypothesis 
We hypothesize that sleep quantity and sleep quality are independently associated with 
the risk of diabetes and their interaction with obesity exacerbates the risk. 
 
3.1.3 Justification 
Sleep duration among Americans has been decreasing since the industrial 
revolution. Type-2 diabetes, a major risk factor for cardiovascular disease (CVD), has 
also been on the rise during the same period. Obesity, a risk factor for type-2 diabetes and 
CVD, has now reached epidemic level in the United States raising health concerns for 
this and future generations. Apart from physical activity and dietary recommendations 
which are yet to have full impacts, the search for opportunities to reduce type-diabetes 
and CVD is an ongoing process. Understanding the relationship between sleep problems 
and type-2 diabetes and how obesity changes the dynamics could fill the gaps in 
knowledge of type-2 diabetes and move us closer to ensuring a healthy nation. 
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3.2.0 METHODS 
 
3.2.1 Study Design: Prospective cohort study of the First National Health and Nutrition 
Examination Survey (NHANES 1).  
3.2.2 Study Participants: Participants were selected from the Epidemiologic Follow-up 
Study of the First National Health and Nutrition Examination Survey (NHANES 1) 
between 1982 and 1992. NHANES is a survey designed to assess the health and 
nutritional status of the non-institutionalized population of the United States151. There 
were a total of 12,220 records at baseline (1982-1984) which indicated a response to at 
least one of the questions on sleep quality or quantity. However, among these 12,220 
records are included some responses collected by proxy for individuals deceased between 
1982 and 1984, and since this is a longitudinal study, only participants who were alive at 
baseline (n=10,523) were included. Further exclusions include participants who were 
diabetic at baseline (n=888). This resulted in sample size of 9635. 
 
3.2.3 Exposure Assessment 
The following questions were used to assess sleep quality: “(1) how often do you 
have trouble falling asleep? (2) how often do you have trouble with waking up during the 
night? (3) how often do you have trouble waking up too early and not being able to fall 
asleep? (4) how often do you get so sleepy during the day or evening that you have to 
take a nap?”. Responses to each of these questions were based on a 5-point scale 
(“Never”, “Rarely”, “Sometimes”, “Often”, and “Almost always”). These responses were 
summed up across the 4 sleep problem items to form the sleep quality variable. Our 
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preliminary analyses did not show significant differences between responses “Never” and 
“Rarely” and diabetes and between “Often”, and “Almost always” and diabetes. Hence to 
ensure adequate sample size in our response categories for valid results these categories 
were combined. The resulting sleep quality classes are: (1) “good sleep” (subjects who 
“never” or “rarely” have sleep problems); (2) “moderate sleep” (subjects who 
“sometimes” have sleep problems); (3) “poor sleep” (subjects who “often”, or “almost 
always” have sleep problems). A sleep quantity indicator was created based on a single 
question, “how many hours of sleep do you usually get per night?” The sleep quantity 
indicator was categorized as <7 hours of sleep, 7 to 9 hours of sleep, and >9 hours of 
sleep. 
 
3.2.4 Diabetes Assessment 
 
Incidence of diabetes from baseline (1982-1984) to 1992 was ascertained from 
self-reports by subjects (physician diagnosed), and from primary recorded cause of death 
(ICD-9: 250-250.93) for those who were deceased during follow-up, but did not report a 
diagnosis of diabetes prior to death. 
 
3.2.5 Assessment of Covariates 
 
Age of subjects at baseline was categorized into 4 groups (<45, 45-54, 55-68, and 
>68). The cut-points were set to ensure an adequate number of subjects in all classes, and 
to take into account the effect of age on both sleep and diabetes. Race/ethnicity was 
categorized as “white”, “black” or “other”, where “other” includes Asian or Pacific 
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Islanders, American Indians, and Eskimos. BMI was categorized as “normal” (<25.0), 
“overweight” (25-29.9), and “obese” (≥30). Blood pressure was categorized as “normal”, 
“prehypertension”, and “hypertension” according to the Seventh report of the Joint 
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood 
Pressure (JNC VII) criteria 152. Self-reported cigarette smoking was classified as “never 
smoker”, “former smoker”, and “current smoker”, while self-reported alcohol 
consumption was classified as “abstainer”, “light drinker”, “moderate drinker”, and 
“heavy drinker”. Self-reported physical activity was classified as “very active”, 
“moderately active”, and “quite Inactive”, and educational status will be categorized as 
“<high school”, “high school”, and “> high school”. Self-reported coffee drinking and 
depression were assessed as “yes or no”.  
 
3.2.6 Statistical Analyses 
 
Chi-square tests were used to test whether categorical variables differed across the 
levels of sleep quantity and quality. Associations between continuous covariates with 
sleep quantity and quality were estimated using analysis of covariance. Lastly, Cox 
proportional hazards models were used to estimate the association between sleep quantity 
and sleep quality and time to onset of diabetes in the study sample. Various models were 
constructed: Model 1 was unadjusted, Model 2 adjusted for age, and Model 3 adjusted for 
Age, BMI, Sex, Race, Hypertension, Cigarette Smoking, Alcohol Consumption, 
Depression, Coffee Drinking, Physical Activity, and Education. Model variables were 
selected because they are known to influence both sleep and diabetes.  A final model 
included an interaction term for BMI and sleep (quantity and quantity). A likelihood ratio 
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test was used to check for possible interaction between BMI and sleep. A significance 
level of 0.05 was used to determine all significant associations. All analyses were 
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). 
 
3.2.7 Power Calculation (Sleep Inadequacy and Type-2 Diabetes) 
 
3.2.8 Prevalence of sleep problems in the U.S population 
An estimated 70 million Americans suffer sleep problems (that is, about 23% of 
the U.S population by 2010 census)153.  This include sleep restriction, primary sleep 
disorders (various forms of sleep disorders affecting people of all ages) , and secondary 
sleep disorders (common in people with a chronic disease, or an alcohol or substance 
abuse disorder, accompanied with poor sleep quality and excessive daytime sleepiness). 
Of 9284 subjects who self-reported their sleep quality, 39.9% of them reported poor sleep 
quality. This gives an exposed group of 3640 and unexposed group of 5644 in terms of 
sleep quality.  
3.2.9 Prevalence of type-2 diabetes among exposed and unexposed groups 
11.3% of Americans ≥20 years have diabetes154. In this study however, the 
proportion of subjects with poor sleep quality who are diabetic is 6.3%, and the 
proportion of subjects with good or moderate sleep who are diabetic is 4.1%. Assuming 
95% confidence level, the power of the study is more than 80% as shown in table 9. 
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Table 9: Power calculation for the association between sleep inadequacy and type-2-
diabetes 
Power for Cohort Studies (Sleep Inadequacy and Type-2-Diabetes) 
 Exposed Group Unexposed Group 
   
Sample Size 3640 5644 
 
Prevalence (or) Coverage (%) 6.3 4.1 
   
Power based on:   
Normal approximation 99.75% 
 
Normal approximation with continuity 
correction 
 
99.71% 
 
 
3.3 RESULTS 
 
Over the 10 year follow-up period, there were 465 incident cases of diabetes 
(4.8%). The mean age and BMI of study subjects were 56 years and 26.0, respectively. 
Females formed 62.8% of the study sample and most of the subjects were white (86.8%). 
53.8% of the subjects were either overweight or obese and 71.1% were either 
prehypertensive or hypertensive. Current cigarette smokers form 28.4% of the sample 
and moderate to heavy drinkers form 11.6%. The study sample was also characterized by 
high school education or more (63.1%), and physically very active individuals form 
28.2%. Subjects who had an income of $25,000 or more form 36.9% of the sample, 
coffee drinkers 86.2%, and depressed subjects 2.5%.  
Covariates more likely to lead to poor sleep quality were increasing age, 
overweight/obesity, white race, female sex, high blood pressure, depression, less than 
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$25,000 of income, physical inactivity, and less than high school educational status. On 
the other hand, current cigarette smoking and light to moderate alcohol consumption 
appear to promote good sleep quality [Table 10]. Sleep quality and quantity were treated 
in this study as independent predictors of diabetes because a test of interaction between 
them did not reach statistical significance (p=0.3751). Results from the Cox proportional 
hazards model showed that poor sleep quality was significantly associated with diabetes 
in the unadjusted model (HR=1.63, 95%CI=1.26-2.10). The association remained 
significant in the age-adjusted (HR=1.36, 95% CI=1.04-1.76) and multivariable adjusted 
(HR=1.47, 95%CI=1.09-1.99) models. Compared with 7 to 9 hours of sleep, subjects 
who slept for less than 7 hours and those who slept for more than 9 hours are 
significantly at risk of diabetes in unadjusted and age adjusted models. The association 
however did not reach statistical significance when all relevant covariates were adjusted 
for [Table 12].  
A joint effect of BMI and sleep quantity on diabetes was considered but was not 
significant (p=0.5879). A significant interaction effect between BMI and sleep quality on 
diabetes however was found (p=0.0151). It was found that obese subjects who have poor 
sleep quality were at a much greater risk of diabetes compared to those with normal BMI 
and good sleep patterns (HR=31.11, 95%CI=11.37 – 85.17) after adjusting for age, sex, 
race, hypertension, cigarette smoking, alcohol consumption, depression, coffee drinking, 
physical activity, educational status, and sleep quantity [Table 13]. In order to find 
absolute risk estimates for the effect of sleep quality on diabetes, 1 unit change in sleep 
quality was evaluated within each category of BMI. Within the obese BMI category 1 
unit change in sleep quality was associated with 1.270 (1.037-1.556) risk of diabetes; 1 
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unit change in sleep quality does not appear to have an effect on diabetes among 
overweight subjects (HR=0.996; 95%CI=0.795-1.248); and within the normal BMI 
category, 1 unit change in sleep quality was associated with 1.557 (1.107 – 2.191) risk of 
diabetes [Table 14]. 
 
3.4 DISCUSSION  
Previous investigations of the effect of sleep duration on diabetes risk have found 
U-shaped relationships; with too little or too much sleep leading to an increased risk of 
diabetes. The mechanisms by which sleep deprivation could contribute to diabetes have 
been established but little is known about how excess sleep could increase the risk of 
diabetes. Possible explanations for the association between excess sleep and diabetes 
include: (1) other medical conditions associated with diabetes resulting in longer time in 
bed, or (2) less physical activity due to more time spent in bed.  The effect of sleep 
quantity on diabetes has demonstrated this U-shaped relationship with <7 hours and >9 
hours of sleep having higher risk estimates compared to the reference group 7-9 hours of 
sleep [Table 12]. In our multivariable model without considering interactions, we found 
elevated risks for diabetes for both short (HR=1.06; 95% CI=0.85-1.32) and long sleep 
(HR=1.46; 95%CI=0.93-2.30) when compared with the referent (7-9 hours), although 
these were not significant after adjusting for confounding factors [Table 12].    
Gangwisch et al129 found an odds ratio of 1.47 (1.03-2.09) for the effect of sleep 
duration of ≤ 5 hours on diabetes, and 1.52 (1.06-2.17) for the effect of ≥9 hours of sleep 
on diabetes, with 7 hours of sleep as the reference group. The main difference between 
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the effect estimates of sleep duration from this study and that of Gangwisch et al., is that 
whilst Gangwisch et al., made 7 hours as their reference group and estimated risks for ≤ 
5, 6, 8, and ≥9 hours of sleep, this study estimated the effects for <7 and >9 hours of 
sleep with 7-9 hours of sleep as referent. This was done to conform to recommendations 
by the National Sleep Foundation (NSF) that adults need 7-9 hours of sleep per night for 
proper functioning. Therefore estimating risk for sleep quantity below and above the 
recommended amount could be easily interpreted within the guidelines of the NSF. 
Rafalson et al.,155 in a nested case-control study, found a threefold increased risk of 
diabetes (OR=3.0; 95%CI=1.05 - 8.59) for sleep duration <6.0 hrs compared to 6 to 8 hrs. 
As already explained, the difference in estimates may be due to differences in the sleep 
duration classifications adopted. Longitudinal studies by Yaggi et al.,132, Ayas et al.,156 
and Tuomilehto et al.,157 did not find significant associations between short sleep duration 
and diabetes. Since ours was also a longitudinal analysis, it raises questions as to which 
study design best estimates the effect of sleep duration on diabetes.  
Longitudinal studies on sleep quality and diabetes have received much attention 
because many of them found significant risk estimates. Kawakami et al.,158 found a 
threefold increased risk of diabetes (HR=2.98; 95%CI=1.36 – 6.53) among subjects who 
have “high” compared to “low” difficulty initiating sleep. They also found that “high” 
difficulty maintaining sleep doubles the risk of diabetes compared to “low” (HR=2.23; 
95%CI=1.08 – 4.61). In our fully adjusted model, poor sleep quality significantly 
increased the risk of diabetes (HR=1.47; 95%CI=1.09-1.99). Our effect estimate was 
different than those reported by Kawakami et al., and may be due to the fact that they 
studied only males and did not adjust for number of hours of sleep. Moreover, our sleep 
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quality variable was formed from four different questionnaire items whilst estimates by 
Kawakami et al., were based on either difficulty initiating sleep or difficulty maintaining 
sleep. Meisinger et al.,133 also found “difficulty maintaining sleep” to be significantly 
associated with diabetes (Males: HR=1.60, 95%CI=1.05 – 2.45; Females: HR=1.98, 95% 
CI=1.20 – 3.29). Meisinger et al., did not consider duration of sleep and males and 
females were analyzed separately, making their estimates to be slightly different from 
what we observed.  
Sleep quality issues can be attributed to many factors including but not limited to 
depression, excessive alcohol consumption, physical inactivity, and sleep apnea. These 
factors could independently or in combination disrupt sleep and contribute to diabetes. 
Longitudinal studies by Marshall et al.,150 Botros et al.,130 and Celen et al.,131 have all 
found significant associations between obstructive sleep apnea and diabetes while Al-
Delaimy et al.,159 found that occasional and regular snoring increased the risk of diabetes. 
Our estimate is similar to those of Botros et al., (HR= 1.43, 95%CI: 1.10-1.86) and Al-
Delaimy et al., (occasional snoring: RR=1.41, 95% CI: 1.22 - 1.63; regular snoring 
RR=2.03, 95%CI: 1.71 - 2.40), but very different from those by Marshall et al., 
(moderate- to- severe OSA: OR= 13.45, 95% CI=1.59 - 114.11) and Celen et al., (OSA in 
women; OR=11.78, 95%CI: 1.14-121.7). Marshall et al., had only 9 incident diabetes 
cases out of 295 subjects over a 4 year period which explains their wide confidence 
interval, and Celen et al., had only 31 women involved in their study out of which 7 had 
diabetes during follow-up leading to a wide confidence interval as well.    The 
longitudinal study by Bjorkelund et al.,135 combined some components of sleep duration 
and quality. Their risk estimate however was insignificant although similar to ours in 
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magnitude (HR=1.35; 95%CI= 0.89 – 2.10). Bjorkelund et al., combined three items (1) 
sleep complaints, (2) use of sleeping pills, and (3) sleep <6h in 24hrs, and categorized the 
composite sleep problem variable as “yes” or “no”. This dichotomization may cause loss 
of vital information rendering the statistical test insignificant.  
While risk estimates from longitudinal studies remain conflicting, those from 
cross-sectional studies have been consistent. Cross-sectional studies by Kachi et al.,160, 
Lou et al.,161, Chao et al.,162, Hsieh et al.,163, Tuomilehto et al.,164, Chaput et al.,165, and 
Gottlieb et al.,166 have all found significant associations between short sleep duration and 
risk of diabetes. Cross-sectional studies measure both exposure and outcome at the same 
time and it may be possible that the short sleep duration was as a result of some other 
health condition or even as a result of diabetes. In addition, these studies estimated only 
the effect of short sleep duration on diabetes without considering the effect of sleep 
quality. In contrast, the cross-sectional study by Jongoh Kim et al.,167 did not find any 
association between sleep duration and diabetes in the entire study sample of 1,652 
Korean men. However, after stratification by abdominal obesity, they did find an 
increased risk of diabetes among 1,241 of the men without abdominal obesity and who 
sleep duration of ≤5 hours per day. We did not find significant association between sleep 
duration and diabetes and we did not perform stratified analyses of sleep duration by BMI 
because our test for interaction between sleep duration and BMI was not significant. 
However, the pattern is similar if short sleep duration is taken to be a proxy for poor sleep 
quality. 
Cross-sectional studies by Ronksley et al., 168 and Reichmuth et al.,169 found that 
sleep apnea significantly increased the risk of diabetes in both males and females. This is 
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consistent with findings from our longitudinal analysis that poor sleep quality 
significantly increased the risk of diabetes. The cross-sectional study by Vgontzas et 
al.,136 did not find individual associations between insomnia and diabetes, or sleep 
duration and diabetes, but after examining the joint effects of insomnia and sleep 
duration, they found that compared to normal sleeping subjects (sleep duration of >6 
hours), those with insomnia and with short sleep duration (<5 hours) were at increased 
risk of diabetes. Our sleep quality variable was composed of items other than insomnia 
and although we did not stratify on number of hours of sleep, we found a significant 
relationship between poor sleep quality and diabetes after adjusting for confounders 
including sleep duration. Mahmood et al.,134 however did not find significant association 
between obstructive sleep apnea and diabetes after adjusting for confounding variables. 
The study by Mahmood et al., was predominantly African Americans (67%), whereas our 
study was predominantly Caucasian (87%). This vast difference in ethnicity between the 
two studies could be a reason for differences in effect estimates. Most of the cross-
sectional associations have been consistent but they cannot show a causal direction. We 
have found in our prospective study a risk estimate of 1.47 for the effect of poor sleep 
quality on diabetes risk, and it is statistically significant.  
Obesity is a known risk factor for diabetes, but the effect of its interaction with 
sleep on diabetes as reported here has not been specifically investigated and reported. We 
found 31 fold increased risk of diabetes among obese subjects with poor sleep quality 
when compared to normal weight subjects with good sleep quality [Table 13]. The hazard 
ratio for the effect of poor sleep quality on diabetes was only 1.47 [Table 12] when BMI 
served as confounder. Effect sizes of around 1.47 have been common because researchers 
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often treat BMI as a confounding variable which makes it impossible for the full public 
health impact of sleep and obesity on diabetes to be assessed. Poor sleep quality could 
cause changes in appetite regulating hormones, leptin and ghrelin, which may lead to 
weight gain and obesity, and subsequently diabetes148. Other mechanisms by which poor 
quality sleep increases diabetes risk include overactivity of the sympathetic nervous 
system, increased inflammation, elevated evening cortisol levels, all of which leads to 
reduced insulin sensitivity and diabetes. Poor sleep has also been proposed to result in 
reduced energy expenditure which could also affect weight status and ultimately diabetes 
149. Among normal BMI subjects 1 unit change in sleep quality (good-moderate-poor) 
was associated with 1.557 (1.107-2.191) risk of diabetes. Among obese subjects 1 unit 
change in sleep quality was associated with 1.270 (1.037-1.556) risk of diabetes. Sleep 
quality did not appear to influence the risk of diabetes among overweight subjects [Table 
14]. In other words overweight subjects have a baseline risk of diabetes which is higher 
than that of normal weight subjects [Table 13] but once that point is reached then the 
effect of sleep does not seem to matter.  
We were able to show in this study that sleep duration and sleep quality have 
independent influences on diabetes risk. Furthermore, we found that BMI modify the 
effect on sleep quality on diabetes. The prospective nature of the study also enhances our 
analysis because we could establish temporality. Only subjects who were alive at the start 
of the study were included to eliminate errors that arise from proxy responses. Our study 
has limitations as well. All the information provided in this document on sleep was self-
reported by subjects and could potentially bias the findings; a sleep study on the subjects 
can solve this problem. However it has been shown that the use of self-reported sleep, 
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characterized by the dimensions used in this study, provides just as good a measure as 
when monitored 170. Also, only a single record of sleep documented at baseline (1982-
1984) was used, instead of multiple records. Sleep habits may change over time and 
cause misclassification of subjects on the exposure. However, it is not likely these 
misclassifications would change findings significantly because they would be non-
differential.  
 
3.5 CONCLUSION 
Poor sleep quality has been found to significantly increase the risk of diabetes in 
the NHANES 1 Epidemiologic Follow-up Study. When the joint effect of obesity was 
considered, the effect of sleep quality on diabetes was found to be exacerbated among 
normal weight subjects. Obese subjects already have higher baseline risk of type-2-
diabetes and although sleep quality does matter, the difference was not as large as found 
among normal weight subjects. Sleep cycles influence hormone levels, such as cortisol 
and growth hormone, as well as inflammation processes evidenced by effects on markers 
of inflammation, such as TNF-α and IL-6. Therefore, poor quality sleep could disrupt 
hormone and inflammation responses, so that poor sleep over time may lead to impaired 
glucose tolerance and diabetes. Poor sleep patterns also influences energy expenditure, in 
part through the disruption of  hunger suppressing and stimulating hormones which are 
also thought to be contributing factors to obesity and hence diabetes. The risk estimates 
of interaction between poor sleep quality and BMI found in this study warrants some 
attention. Thus, we recommend weight management efforts to be intensified and sleep 
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problems reduced with every available resource in order to reduce the incidence of 
diabetes. Additional studies are needed to examine the effect of sleep on diabetes risk 
among overweight individuals and to explain possible biologic mechanisms why sleep 
quality may not be an important risk factor for diabetes among overweight individuals. 
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Table 10: Baseline Characteristics by sleep quality 
  Sleep Quality  
  Good Moderate Poor  
Baseline Characteristics N N=2180 N=3464 N=3640 F (P-value) 
      
Age, y:  Mean (SD) 9284 51.0 (13.3) 54.2 (14.0) 60.9 (14.6) 743.04 (<.0001 
BMI: Mean (SD) 9129 26.0 (4.8) 26.0 (4.8) 26.1 (4.9) 1.51 (0.2195) 
      
Age Category, n(%)     X2(P-value) 
<45                                 2579 887 (34.4) 1085 (42.1) 607 (23.5)  
45-54                              2213 564 (25.5) 881 (39.8) 768 (34.7)  
55-68                              2194 430 (19.6) 828 (37.7) 936 (42.7)  
>68                                 2298 299 (13.0) 670 (29.2) 1329 (57.8) 699.36(<.0001) 
       
BMI Category, n(%)      
<25.0                              4217 1020 (24.2) 1617 (38.3) 1580 (37.5)  
25-29.9                           3270 771 (23.6) 1193 (36.5) 1306 (39.9)  
>29.9                              1642 366 (22.3) 600 (36.5) 676 (41.2) 9.13 (0.0580)  
      
RACE      
White   8063 1811 (22.5) 3021 (37.5) 3231 (40.1)  
Black 1132 345 (30.5) 402 (35.5) 385 (34.0)  
Other 89 24 (27.0) 41 (46.1) 24 (27.0) 43.23 (<.0001) 
      
SEX      
Male 3457 939 (27.2) 1252 (36.2) 1266 (36.6)  
Female 5827 1241 (21.3) 2212 (38.0) 2374 (40.7) 42.95 (<.0001) 
      
HYPERTENSION      
Normal 2601 744 (28.6) 1038 (39.9) 819 (31.5)  
Prehypertensive 3645 836 (22.9) 1365 (37.5) 1444 (39.6)  
Hypertensive 2756 552 (20.0) 971 (35.2) 1233 (44.7) 112.26 (<.0001 
      
SMOKING      
Never 4183 950 (22.7) 1567 (37.5) 1666 (39.8)  
Former 2464 545 (22.1) 884 (35.9) 1035 (42.0)  
Current 2636 685 (26.0) 1013 (38.4) 938 (35.6) 26.47 (<.0001) 
      
ALCOHOL      
Abstainer    3902 827 (21.2) 1382 (35.4) 1693 (43.4)  
Light Drinker                 4282 1077 (25.2) 1647 (38.5) 1558 (36.4)  
Moderate  Drinker          999 251 (25.1) 403 (40.3) 345 (34.5)  
Heavy Drinker                76 18 (23.7) 25 (32.9) 33 (43.4) 55.07 (<.0001) 
      
PHYSICAL ACTIVITY      
Very Active                   2601 773 (29.7) 979 (37.6) 849 (32.6)  
Moderately Active         5148 1135 (22.1) 2023 (39.3) 1990 (38.7)  
Quite Inactive                1488 264 (17.7) 449 (30.2) 775 (52.1) 186.27 (<.0001 
COFFEE      
Yes 7998 1865 (23.3) 2961 (37.0) 3172 (39.7)  
No 1276  314  (24.6) 499 (39.1) 463 (36.3) 5.26 (0.0721) 
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Table 10: Baseline Characteristics by sleep quality (Continued) 
  Sleep Quality  
  Good Moderate Poor  
Baseline Characteristics N N=2180 N=3464 N=3640 X2 (P-value) 
      
DEPRESSION      
Yes 229 26 (11.4) 62 (27.1) 141 (61.6)  
No 8973 2138 (23.8) 3369 (37.6) 3466 (38.6) 51.33 
(<.0001)       
INCOME, $      
<10000                           2389 369 (15.5) 810 (33.9) 1210 (50.6)  
10,000-24,999                3036 733 (24.1) 1088 (35.8) 1215 (40.0)  
25,000-49,000                2374 699 (29.4) 982 (41.4) 693 (29.2)  
>50,000                          805 250 (31.1) 323 (40.1) 232 (28.8) 305.14 
(<.0001       
EDUCATION      
<HS 3404 653 (19.2) 1147 (33.7) 1604 (47.1)  
HS 3456 862 (24.9) 1352 (39.1) 1242 (35.9)  
>HS 2372 656 (27.7) 945 (39.8) 771 (32.5) 157.52 
(<.0001       
DIABETES      
Yes 447 82 (18.3) 150 (33.6) 215 (48.1)  
No                                  8837 2098 (23.7) 3314 (37.5) 3425 (38.8) 16.52 
(0.0003)       
SLEEP QUANTITY (hrs)      
<7 6095 1592 (26.1) 2545 (41.8) 1958 (32.1)  
7-9 2599 453 (17.4) 729 (28.1) 1417 (54.5)  
>9 293 63 (21.5) 91 (31.1) 139 (47.4) 393.0 
(<.0001)  
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Table 11: Baseline characteristics by sleep quantity 
  Sleep Quantity (hrs)  
  <7 7-9 >9  
Baseline Characteristics N N=2599 N=6096 N=293 F (P-value) 
      
Age, y:  Mean (SD) 8988 56.0 (14.5) 55.6 (14.5) 66.7 (15.0) 64.94 (<.0001) 
BMI: Mean (SD) 8842 26.5 (5.0) 25.9 (4.8) 26.1 (5.1) 22.45 (<.0001) 
      
Age Category, n(%)     X2(P-value) 
<45                                 2491 699 (28.1) 1756 (70.5) 36 (1.4)  
45-54                              2149 699 (31.1) 1447 (67.3) 33 (1.6)  
55-68                              2118 598 (28.2) 1456 (68.8) 64 (3.0)  
>68                                 2230 633 (28.4) 1437 (64.4) 160 (7.2) 161.54 
(<.0001       
BMI Category, n(%)      
<25.0                              4092 1084 (26.5) 2884 (70.5) 124 (3.0)  
25-29.9                           3158 942 (29.8) 2114 (67.0) 102 (3.2  
>29.9                              1592 528 (33.2) 1013 (63.6) 51 (3.2) 28.14 (<.0001) 
      
RACE      
White   7834 2181 (27.8) 5421 (69.2) 232 (3.0)  
Black 1067 383 (35.8) 624 (58.5) 61 (5.7)  
Other 87 36 (41.4) 51 (58.6) - 67.04 (<.0001) 
      
SEX      
Male 3334 972 (29.1) 2237 (67.1) 125 (3.8)  
Female 5654 1627 (28.8) 3859 (68.2) 168 (3.0) 4.41 (0.1102) 
      
HYPERTENSION      
Normal 2527 637 (25.2) 1834 (72.6) 56 (2.2)  
Prehypertensive 3535 1068 (30.2) 2366 (66.9) 101 (2.9)  
Hypertensive 2666 811 (30.4) 1735 (65.1) 120 (4.5) 51.13 (<.0001) 
      
SMOKING      
Never 4067 1093 (26.9) 2823 (69.4) 151 (3.7)  
Former 2377 697 (29.3) 1606 (67.6) 74 (3.1)  
Current 2543 809 (31.8) 1666 (65.5) 68 (2.7) 22.31 (0.0002) 
      
ALCOHOL      
Abstainer    3814 1074 (28.2) 2565 (67.2) 175 (4.6)  
Light Drinker                 4122 1207 (29.3) 2822 (68.4) 93 (2.3)  
Moderate  Drinker          954 283 (29.7) 650 (68.1) 21 (2.2)  
Heavy Drinker                75 31 (41.3) 42 (56.0) 2 (2.7) 44.0 (<.0001) 
      
PHYSICAL ACTIVITY      
Very Active                   2517 765 (30.4) 1694 (67.3) 58 (2.3)  
Moderately Active         4991 1365 (27.4) 3480 (69.7) 146 (2.9)  
Quite Inactive                1440 461 (32.0) 898 (62.4) 81 (5.6) 54.09 (<.0001) 
COFFEE      
Yes 7750 2247 (29.0) 5269 (68.0) 234 (3.0)  
No 1229 349 (28.4) 821 (66.8) 59 (4.8) 10.66 (0.0048) 
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Table 11: Baseline Characteristics by sleep quantity (Continued) 
  Sleep Quantity  
  1 2 3  
Baseline Characteristics N N=2599 N=6096 N=293 X2 (P-value) 
      
DEPRESSION      
Yes 222 83 (37.4) 127 (57.2) 12 (5.4)  
No 8687 2497 (28.7) 5912 (68.1) 278 (3.2) 12.58 (0.0019) 
      
INCOME, $      
<10000                           2332 739 (31.7) 1447 (62.0) 146 (6.3)  
10,000-24,999                2926 840 (28.7) 2011 (68.7) 75 (2.6)  
25,000-49,000                2310 617 (26.7) 1665 (72.1) 28 (1.2)  
>50,000                          773 220 (28.4) 548 (70.9) 5 (0.7) 150.64 (<.0001 
      
EDUCATION      
<HS 3302 1012 (30.7) 2101 (63.6) 189 (5.7)  
HS 3341 970 (29.0) 2306 (69.0) 65 (2.0)  
>HS 2294 602 (26.2) 1659 (72.3) 33 (1.5) 129.24 (<.0001 
      
DIABETES      
Yes 427 141 (33.0) 263 (61.6) 23 (5.4)  
No                                  8561 2458 (28.7) 5833 (68.1) 270 (3.2) 11.40 (0.0034) 
      
SLEEP QUALITY      
Good 2108 453 (21.5) 1592 (75.5) 63 (3.0)  
Moderate 3365 729 (21.7) 2545 (75.6) 91 (2.7)  
Poor 3514 1417 (40.3) 1958 (55.7) 139 (4.0) 393.0 (<.0001) 
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Table 12: Hazard Ratios for Sleep Quality and Quality as risk factors for Type-2 Diabetes 
 Sleep Quality  
   
 Good Moderate Poor  
     
Baseline 
Characteristics 
 HR (95%CI) HR (95%CI) P-value 
     
Model  1 Referent 1.16 (0.89-1.52) 1.63 (1.26-2.10) 0.0001 
 
     
Model  2 Referent 1.09 (0.83-1.43) 1.36 (1.04-1.76) 0.0356 
     
Model  3 Referent 1.28 (0.95-1.72) 1.47 (1.09-1.99) 0.0392 
     
 Sleep Quantity (hours)  
     
 7-9 <7 >9 P-value 
     
Model  1 Referent 1.26 (1.03-1.55) 1.93 (1.26-2.96) 0.0022 
     
Model  2 Referent 1.25 (1.02-1.53) 1.56 (1.02-2.41) 0.0244 
     
Model  3 Referent 1.06 (0.85-1.32) 1.46 (0.93-2.30) 0.2570 
Model 1 was unadjusted. Model 2 was Age-adjusted. Model 3 was adjusted for Age, Sex, BMI, Race, 
Hypertension, Cigarette Smoking, Alcohol Consumption, Depression, Coffee Drinking, Physical Activity, 
and Education. The model 3 for sleep quality was adjusted for sleep quantity; likewise the model 3 for 
sleep quantity was adjusted for sleep quality. 
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Table 13: Effect of the interaction of BMI and Sleep Quality on Type-2 Diabetes 
 HR (95% CI) HR (95% CI) HR (95% CI) 
 Good Sleep Moderate Sleep Poor Sleep 
Normal BMI (Referent) 4.70 (1.66-13.33) 4.55 (1.61-12.90) 
     Overweight 8.97 (3.12-25.50) 8.28 (2.97-23.10) 8.74 (3.15-24.22) 
     
Obese 19.88 (7.00-56.49) 23.32 (8.45-64.34) 31.11 (11.37-85.17) 
Model adjusted for age, sex, race, hypertension, cigarette smoking, alcohol consumption, 
depression, coffee consumption, physical activity, education, and sleep quantity.  
 
 
Table 14: Effect of 1-unit change in sleep quality on type-2 diabetes within BMI classes 
 Hazard Ratio 95% CI 
Normal BMI 1.557 1.107 – 2.191 
   
Overweight 0.996 0.795 – 1.248 
   
Obese 1.270 1.037 – 1.556 
Model adjusted for age, sex, race, hypertension, cigarette smoking, alcohol consumption, 
depression, coffee consumption, physical activity, education, and sleep quantity. 
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CHAPTER FOUR 
 
FACTORS AFFECTING TELOMERE LENGTH: THE ROLE OF OXIDATIVE 
STRESS 
 
4.1 INTRODUCTION 
It has been established that telomere shortening decreases the proliferative 
potential of the cells of the organism and causes aging of the organism. Aging has long 
been known to be associated with decreased immune system function which implies that 
shorter telomeres may be involved in compromising immune system function leading to 
some of the late-life diseases in humans. Research has subsequently established that 
telomere length is a biomarker of cumulative exposure to oxidative stress and a 
prognostic indicator for risk of late-life diseases89, 171.  Telomere shortening has been 
associated with neurodegenerative diseases, infections, diabetes, malignancies, 
autoimmune diseases, hypertension, atherosclerosis, cardiovascular disease, and mortality 
especially from cardiovascular disease172-178.  It is therefore of importance to public 
health to identify factors associated with oxidative stress that contribute to telomere 
length shortening with the aim that modifying these factors may reduce telomere attrition 
and hence protect health. Factors such as obesity, physical inactivity, excessive use of 
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alcohol, and use of tobacco products have been associated with increased oxidative stress 
but research is limited on which of these factors actually contribute to telomere 
shortening80, 81, 83, 84, 86, 88. This research is focused on identifying factors that influence 
telomere length in order to contribute to available literature on telomere biology which is 
important in improving human health.   
 
4.1.1 Aim 
This study investigates the effect of oxidative stress on telomere length in the 
Framingham Heart Study (FHS). Factors associated with oxidative stress such as body 
mass index, physical activity, tobacco use, and alcohol use will be investigated as to their 
influence on telomere length. 
 
4.1.2 Hypothesis 
We hypothesize that factors that increase oxidative stress such as increasing BMI 
(obesity), high tobacco and alcohol use, and physical inactivity will be associated with 
shorter telomeres. 
 
4.1.3 Justification 
 
Telomere length shortening has been found in previous studies to be the 
cumulative effect of oxidative stress and inflammation. Leucocyte telomere length 
therefore is a dependable predictor of past metabolic history in biological organisms171. 
Shorter telomeres have been linked to aging and age-related diseases and the search for 
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ways to reduce telomere length shortening cannot be overemphasized. Identifying factors 
that increase oxidative stress and therefore accelerate telomere length shortening is 
important to ensuring good health. 
 
4.2 METHODS 
4.2.1 Study Design: Cross-sectional study of the association between telomere length 
and body mass index, physical activity, tobacco use, and alcohol use.   
 
4.2.2 Study Participants: This study enrolled subjects from the offspring cohort of the 
Framingham Heart Study (FHS). The FHS is a health research project started in 1948 
under the direction of the National Heart, Lung, and Blood Institute (NHLBI) with the 
objective to identify the common factors that contribute to CVD. A total of 5,209 men 
and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, 
were enrolled in the study. A second generation cohort made up of 5,124 offspring of the 
participants of the original cohort was enrolled in 1971. The participants underwent 
extensive physical examinations and lifestyle interviews at baseline, and followed up 
every two years thereafter. The FHS is one of the most well-organized cohorts in 
scientific research and has extensive information on major CVD risk factors such as high 
blood pressure, smoking, obesity, diabetes, and physical inactivity. Studies based on the 
FHS have contributed immensely to scientific literature over the last 50 years, and the use 
of this cohort for our present research provides us with the advantage of quality medical 
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and physical examinations, and laboratory tests, which are important in conducting valid 
research179. 
 
4.2.3 Inclusion Criteria 
The offspring cohort was used for this study. The ages of the participants of the 
offspring cohort at baseline ranged from 5 to 70 years (n=5,124). Participants without 
history of any overt cardiovascular disease were included in this study.  In addition, only 
participants with telomere length records were included.  
4.2.4 Exclusion Criteria 
Participants whose telomere lengths could not be determined either due to 
insufficient amount of DNA or poor DNA quality were excluded from this study (345 of 
such exclusions were made in previous studies180, 181). A resultant sample of 974 subjects 
was used for this study. 
 
4.2.5 Measurement of Telomere Length 
This study used leukocyte telomere length data of participants provided by FHS. 
An independent laboratory that was blinded to all characteristics of the leukocyte donors 
conducted the telomere length measurements by Southern blot analyses and the results 
transmitted electronically to FHS only by ID numbers174, 180, 181.  
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4.2.6 Assessment and Definition of Covariates 
The FHS after obtaining informed consent, collected detailed physical and 
medical information on all study participants. For this study, hypertension status was 
defined according to the seventh report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) as either 
“Normal”: systolic <120mmHg and diastolic <80mmHg; “Prehypertension”: systolic 
120-139mmHg and diastolic 80-89mmHg; “Hypertension”: systolic ≥140mmHg and 
diastolic ≥90mmHg. Body Mass Index (BMI) was calculated as weight (kg)/height (m)2 
and categorized as normal (BMI <24.99), overweight (BMI 25-29.99), and obese (BMI 
≥30). Self-reported smoking was coded as “never smoker”, “former smoker”, or “current 
smoker”. Energy expenditure was used to assess physical activity and was used as 
quartiles. Alcohol consumption was categorized as “nondrinker” “light”, “moderate”, or 
“heavy” drinker based on number of drinks per week. The alcohol variable used in the 
analyses was a combination of beer, red wine, white wine, and others including highballs 
and cocktails. Light drinking comprised of taking 1-5 drinks per week, moderate drinking 
was 6-13 drinks per week, and 14 or more drinks per week was categorized as heavy 
drinking.  
 
4.2.7 Statistical Analysis 
Generalized linear models (GLM) were used to model the effect of physical 
activity, body mass index, alcohol consumption, and tobacco use on telomere length. 
Telomere length was normally distributed for this sample and did not call for any 
transformation. Adjustments were made for age, gender, and hypertension to prevent 
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confounding by these variables. All analyses were performed using SAS version 9.3. 
Level of significance of all analyses was based on p-value of 0.05. 
 
4.2.8 Power Calculation (factors affecting telomere length) 
 
4.2.9 Prevalence of short telomeres among exposed and unexposed groups 
For the purpose of estimating power for this study, telomere lengths were set at 
median with “short” and “long” telomeres recorded as below and above median, 
respectively. This implies 50% “short” telomere prevalence in the study sample.  
4.2.10 Overweight/Obesity 
More than 50% of U.S adults are overweight or obese182. Among the 974 
Framingham cohort participants with telomere records, overweight or obese individuals 
formed 69.9% resulting in exposed and unexposed samples of 681 and 293, respectively. 
At 95% confidence level and 60% prevalence of short telomere among overweight or 
obese participants, there is more than 80% power for this study [Table 15]. 
4.2.11 Cigarette Smoking 
19.0% of all adults (aged 18 years or older), in the United States smoke 
cigarettes183. Among the 974 Framingham cohort participants with telomere records, we 
found 13.7% current smokers resulting in exposed and unexposed groups of 124 and 784 
respectively. At 95% confidence level and 64% prevalence of short telomere among 
Cigarette smoking participants, there is more than 80% power for this study [Table 15]. 
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4.2.12 Alcohol Use 
Heavy drinking is defined as consuming more than 1 drink per day on average for 
women and more than 2 drinks per day on average for men. 24% of men and 12% of 
women binge drink. Binge drinking is defined as a pattern of alcohol consumption that 
brings the blood alcohol concentration level to 0.08% or more which usually corresponds 
to 5 or more drinks on a single occasion for men or 4 or more drinks on a single occasion 
for women, within hours 184. In this study 33% of subjects consume 6 or more drinks per 
week. Using 33% prevalence of excessive alcohol consumption for both males and 
females and with a total of 974 Framingham cohort participants with telomere records, 
the exposed and unexposed samples were 317 and 644 respectively. At 95% confidence 
level and 59.9% prevalence of short telomere among excessive alcohol users, there is 
more than 80% power for this study [Table 15]. 
4.2.13 Physical Inactivity 
More than 50% of Americans do not meet the Physical Activity Guidelines for 
aerobic physical activity185, and 25% of adults are completely inactive186. We categorized 
physical activity into quartiles, and with the lowest quartile representing physically 
inactive subjects, the exposed and unexposed samples will be 225 and 675 respectively. 
At 95% confidence level and 61.1% prevalence of short telomere among physically 
inactivity participants, there is more than 80% power for this study [Table 15]. 
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Table 15: Power Calculations (factors affecting telomere length) 
 
Variable 
 
Sample 
Exposed 
 
Sample 
Unexposed 
Prevalence 
of short 
telomere in 
exposed 
Prevalence 
of short 
telomere in 
unexposed 
Power 
with 
continuity 
correction 
Overweight/Obesity 681 (69.9%) 293 60% 50% 80.6% 
Current smoking 124 (13.7%) 784 64% 50% 80.1% 
Alcohol use 317 (33.0%) 644 59.9% 50% 80.7% 
Physical Inactivity 225 (25.0%) 675 61.1% 50% 80.4% 
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4.3 RESULTS 
 
A total of 974 subjects were analyzed and the mean age was 58.2 years. Age 
distributions for <50, 50-69, and >69 years were 15.3%, 72.5%, and 12.2%, respectively. 
The mean BMI for the sample was 28.0 with overweight and obese subjects constituting 
69.9%. Females formed 51.4%, and current smokers formed 13.7% of the sample. 
Subjects who did not use alcohol formed 35.4% of the sample, and heavy drinkers (≥14 
drinks/week) formed 13.0%. Subjects who were classified as hypertensive (≥140/90) 
constituted 40.8% of the sample [Table 16]. Telomere length was normally distributed 
with a mean of 6.99kbp (6.99 kilo base-pairs). Unadjusted analyses have shown that 
increasing age, BMI, male gender, and hypertension were significantly associated with 
telomere length shortening, while cigarette smoking, energy expenditure, and alcohol 
consumption were not.  
In the multivariable model age, gender, BMI, and alcohol consumption were 
significantly associated with telomere length [Table 17]. Hypertension and energy 
expenditure were not found to influence telomere length or confound the association 
between telomere length and the other variables in the model and were eliminated from 
further analyses. Cigarette smoking although not significantly associated with telomere 
length in both the unadjusted and multivariable models, it has been found to confound the 
association between alcohol use and telomere length in the multivariable model [Table 
18]. The effect estimate between alcohol use and telomere length was attenuated by the 
presence of cigarette smoking in the model making alcohol use not quite statistically 
significant (p=0.0983) [Table 18]. Age, gender, and BMI were still significantly 
associated with telomere length when cigarette smoking was added to the model. A unit 
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increase in age was associated with 21.1bp (21.1 base-pairs) decrease in telomere length 
(p <.0001) [Table 18]. Compared to subjects below 50 years old, subjects 70 years or 
older have 596bp shorter telomeres (p <.0001) [Table 19]. A unit increase in BMI was 
associated with 8.5bp decrease in telomere length (p=0.0164) [Table 18]. Overweight 
subjects have 73.8bp shorter telomeres compared to normal weight subjects but was 
nonsignificant (p=0.1024), and obese subjects have 113bp shorter telomeres compared to 
normal weight subjects (p=0.0193) [Table 19]. There was no difference between non-
drinkers and light drinkers (1-5 drinks/per week). The non-drinker and light drinker 
classes have therefore been collapsed for comparison with moderate and heavy drinking 
classes. Moderate drinking was associated 18.2 bp shorter telomere length compared to 
the none or light drinker group but the association was nonsignificant (p=0.6999), and 
heavy drinking was associated with 93.1bp shorter telomeres compared to the none or 
light drinker group (p=0.0976) [Table 19].  
 Males were significantly more likely to have shorter telomeres (108.5bp shorter) 
compared to females (p=.0041) [Table 18]. This estimate was attenuated by about 5bp 
but remained significant (p=0.0073) when categories of the other variables were 
considered instead of interval [Table 19]. Current smoking was associated with 69.2bp 
shorter telomeres compared to no smoking but the association did not reach statistical 
significance (p=0.2551). 
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4.4 DISCUSSION  
The results of the study have shown that age, gender, and BMI have significant 
influence on telomere length. The association between aging and telomere attrition has 
long been established.  Telomeres shorten at every cell division and one would expect 
that when all other factors are held constant older people should have shorter telomeres 
compared to younger people. During the formation of peripheral leucocytes there is 
successive division of hematopoietic stem cells and progenitor cells contributing to the 
telomere shortening with age. In this sample, comparing subjects above 50 years old to 
subjects less than 50 years have shown that telomeres shorten at a rate of approximately 
200bp for every 10 years after the age 50. Telomere length therefore has been proposed 
by some researchers to be an indicator of biological age187. Cell division is necessary for 
growth but does not tell the whole story about the shortening of telomeres with age. 
Hence characterizing telomere length as a biological age indicator has been argued 
against by other researchers188. Other proposals put forth to explain the shortening of 
telomeres with age include inflammation and oxidative stress174, 175, 189. Inflammation 
increases the demand for cell replication and hence accelerated shortening of telomeres. 
The number of telomere repeats lost per cell replication has also been found to increase 
due to oxidative stress190-192. Inflammation and oxidative stress play important roles in 
aging and late-life diseases23, 193 and their association with telomere shortening explains 
the increased incidence and prevalence of late-life diseases, particularly cardiovascular 
disease among individuals with shorter telomeres175, 178, 194, 195. The rate of telomere 
shortening with age was investigated by Vaziri et al.,196 among 140 individuals (0-107 
years old) including 21 Down syndrome (DS) patients. They found that among 119 
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unrelated normal individuals, mean telomere length of peripheral blood T lymphocytes 
declined at a rate of 41 bp per year (P < .00005; r = .83). They also found that the rate of 
loss in DS patients was threefold higher than in age-matched normal individuals (rate of 
among DS patients: 133 ± 15 bp/year; rate of loss among age-matched normal 
individuals: 43 ± 7.7 bp/year; P < .0005). Down syndrome is characterized by immune 
function loss which implies that accelerated loss of peripheral blood T lymphocytes could 
be a reflection of immune cell senescence in DS patients. In our study, the rate of 
telomere attrition was 21 bp per year after adjusting for gender, body mass index, alcohol 
use, and cigarette smoking [Table 18]. These adjustments could be a source for the 
differences in estimates between our study and that of Vaziri et al.  Moreover, Vaziri et 
al., were more specific, that is, they measured T lymphocytes rather than a broad category 
of leucocytes. Furthermore, our analyses involved over 900 subjects whilst results by 
Vaziri et al., were based on 140 individuals including 21 DS patients.  
Our analyses also showed a significant difference in telomere length between 
males and females (Males vs. females: β=-103 bp, p=0.0073) [Table 19]. This result also 
conforms to published literature about telomere length differences by gender196, 197.  In 
the study by Vaziri et al., males have a faster rate of loss in telomeric DNA compared to 
females although the difference was not significant (50 ± 4.2 vs. 40 ± 3.6 bp/year, P = .1). 
Bekaert at al.,198 in their investigation into the association between telomere length and 
CVD risk factors also showed that females have significantly longer telomeres compared 
to males. Meta-analyses by Gardner et al.,197 from 36 cohorts (36,230 participants) 
provided further evidence that females on average have longer telomeres compared to 
males. There are many schools of thought concerning the gender difference between 
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males and females. The study by Aubert et al.,199 found that females have longer 
telomeres at birth compared to males, but the difference was not statistically significant.  
Okuda et al.,200 found no evidence of telomere length difference by gender at birth, and 
suggested that longer telomeres in females than males that occur in adulthood could be 
due to slower rate of telomere attrition in females. Slower rate of telomere attrition in 
females could mean reduced oxidative stress because in telomere biology, the influence 
of free radicals is a major component of telomere attrition89.  In support of this it has been 
found that females produce fewer reactive oxygen species than men. This is possible 
through the many actions of estrogen in scavenging free radicals, or inhibiting their 
formation, and ability to stimulate enzymes to detoxify free radicals201. Thus, the 
antioxidant properties of estrogen serve to preserve telomeres of females or at least slow 
the rate of attrition. It is also thought that estrogen might stimulate telomerase to add 
telomere repeats to the ends of chromosomes given that an estrogen-response element is 
present in the telomerase reverse transcriptase201.  Estrogen has also been found to 
stimulate nitric oxide production in vascular endothelial cells, which leads to stimulation 
of telomerase in these cells and could protect against endothelial dysfunction that 
characterize oxidative stress202. 
Obesity is another important factor in telomere biology. It is currently a global 
epidemic and has been implicated in many disease processes. Obesity is characterized by 
a state of high-systematic oxidative stress and inflammation203 and because telomeres are 
very vulnerable to attack by reactive oxygen species204, it has been postulated that 
telomere attrition could be accelerated by obesity. We found in our analysis that a unit 
increase in BMI is associated with 8.5 bp (0.0085 kbp) decrease in telomere length 
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(p=0.0164) [Table 18]. When obese subjects (BMI ≥30) were compared with normal 
subjects (BMI<25), it was found that obesity is associated with 113 bp shorter telomeres 
(p=0.0193) [Table 19]. The study by Fitzpatrick et al.,175 in the Cardiovascular Health 
Study showed similar results when they compared overweight subjects with normal 
subjects (β=-117 bp, p=0.06). Their overweight class however included obese subjects. 
Our sample size was more than twice theirs (419) and may be the reason for their p-value 
of 0.06. Lee et al.,205 also showed that BMI was inversely associated with telomere length 
although they used the ratio of telomere repeat copy number (T) and single-copy gene 
copy number (S),T/S ratio, to estimate telomere length whiles we used terminal 
restriction fragments (TRF) method. 
The study by Diaz et al.,206 involving 317 subjects between the ages of 40 and 64 
did not show any association between BMI and telomere length. Our sample of 974 is 3 
times bigger and could be among reasons for the varying results. A recent meta-analysis 
by Müezzinler et al., gave credence to our results. They found that a unit increase in BMI 
is associated with 8.0 bp (0.008 kbp) decrease in telomere length (p=0.058). Although 
their p-value was only marginally statistically significant, we got approximately the same 
estimate for the effect of BMI on telomere length and this is worth noting. Obesity begins 
with high caloric intake and less physical activity. The result is accumulation of excess 
fat in the adipose tissue, leading to low-grade inflammation, hypoxia and increased free 
radical production207, 208. This alters the secretion of adipokines (adiponectin and leptin) 
and cytokines (TNFα, IL-1β, and IL-6), by the adipose tissue. This then manifests as 
health problems particularly, insulin resistance, diabetes, and atherosclerosis. Obesity 
therefore, is associated with hyperglycemia, high levels of circulating free fatty acids, 
86 
 
decreased antioxidant defenses and chronic inflammation. The resultant enhanced 
oxidative stress could explain the association between obesity and telomere attrition.  
Alcohol consumption and cigarette smoking were not found to significantly 
influence telomere length in our study. Alcohol use was marginally associated with 
telomere length when smoking was not considered [Table 17] but after adjustment for 
cigarette smoking the effect was no longer significant [Table 18]. A study of business 
men in Helsinki209 found that compared with non-drinkers, subjects who drank more than 
one drink per day have significantly shorter telomeres. One drink per day was not found 
to be significantly associated with telomere length and conforms to the protection offered 
by light to moderate drinking as found by some studies. In this study, light drinkers and 
non-drinkers were combined because they these groups were not different in their effects 
on telomere length.  In another study involving Caucasian males living in Northeastern 
Italy, it was found that alcohol abusers have significantly shorter telomeres (almost 
halved) compared to controls. The association was also found in their linear model with 
decreasing telomere lengths associated with increasing amount of drinks per day210. In 
Japan, specimens of the esophagus were collected from 26 alcoholic patients with mean 
age of 61.2 years, and compared with specimens of normal esophageal mucosa obtained 
from 24 autopsy cases with mean age of 73.3 years. When telomeres in the basal cells of 
the esophageal epithelium were measured it was found that those from the alcoholics 
were significantly shorter than the normal controls211. This study focused on telomere 
length from the esophageal mucosa whilst we measured leucocyte telomere length. 
Nevertheless, both studies are comparable in terms of highlighting the harmful effects of 
excessive alcohol consumption. It has been suggested that some alcohol use may be 
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beneficial and the study by Sun et al.,84 has provided evidence. They analyzed 5,862 
women in the Nurses’ Health Study and found that moderate drinking (1 drink/week to 2 
drinks/day), was associated with longer telomere length although the association was not 
statistically significant. They further put together all low-risk factors such as non-current 
smoking, maintaining a healthy body weight, engaging in regular moderate or vigorous 
physical activities, drinking alcohol in moderation, and eating a healthy diet, and found 
that the higher the number of low-risk factors, the longer the telomeres (p= 0.015). Light 
to moderate drinking has also been found to reduce cardiovascular risk in a meta-analysis 
involving 84 studies. The pooled adjusted relative risk for CVD mortality was 0.75 (0.70 
to 0.80) for alcohol drinkers compared to non-drinkers. For coronary heart disease 
mortality, it was found that 1-2 drinks a day provided the lowest risk and for stroke 
mortality the lowest risk was found for drinking ≤1 drink per day212. Another meta-
analysis involving 23 studies has also found that moderate alcohol intake is protective 
against dementia and Alzheimer's disease213. A prospective study of U.S. adults aged 55 
and older in the Health and Retirement Study found that moderate drinking (1 drink/d) 
was strongly associated with less mortality and better risk factor profiles, compared to no 
drinking214. With all the proposed benefits of light to moderate alcohol use, the 
mechanisms influencing telomere shortening are not clearly defined. As outlined earlier, 
telomeres are vulnerable to oxidative stress and it is plausible that alcohol-induced 
increase in oxidative stress, inflammation, and impaired antioxidant systems are the main 
mechanisms linking excessive alcohol use to telomere attrition. 
Cigarette smoking has been linked with telomere shortening although we did not 
find a significant association. Valdes et al.,81 found a dose-response relationship between 
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smoking and telomere length where each pack-year of cigarette smoked was equivalent to 
an additional 5 bp of telomere length lost compared with the rate in the overall cohort 
(p=0.017). Our study categorized smoking as “never”, “former”, and “current” rather 
than pack years and our analysis comprised of males and females together whiles Valdes 
et al., studied only women. In a cross-sectional study of 20 current smokers and 20 non-
smokers, a higher mean pack year of cigarette was found in subjects with negative 
telomerase reverse transcriptase (hTERT) expression in the skin (P < 0.01)215. 
Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by adding the 
telomere repeat “TTAGGG”. The telomerase reverse transcriptase (hTERT) is a catalytic 
subunit of the enzyme telomerase. Hence negative action of smoking on hTERT 
expression implies shorter telomeres. Active smoking was found in the Prevention of 
Renal and Vascular End-stage Disease (PREVEND) study, to almost triple the rate of 
telomere attrition per year (P < 0.0001)216. It is biologically plausible that smoking is 
associated with telomere length which could translate into health related states linked to 
both smoking and shortened telomeres. Cigarette smokers are at higher risk of developing 
several chronic disorders including buildups in arteries, some types of cancer, and 
chronic obstructive pulmonary disease. It has been estimated that 30% of all cancer 
deaths, 20% of all coronary heart diseases and strokes, and 80% of all chronic obstructive 
pulmonary disease are attributable to cigarette smoking. Smoking has been found to be 
the main contributor to lung cancer, atherosclerosis, and myocardial infarctions217-219. 
Smoking could induce oxidative stress and accelerate telomere attrition because cigarette 
smoke contains a large variety of compounds, including oxidants and free radicals that 
are capable of initiating and promoting oxidative damage to tissue proteins.  
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It has been shown in this research that age, gender, and BMI have significant 
effects on telomere length. The associations were strong and conform to existing 
literature on the association between these factors and telomere length. The Framingham 
Heart Study (FHS) from which we performed these analyses is known for high data 
quality which reflects on the validity of our study. Our study however is not devoid of 
limitations. Firstly, we performed a cross-sectional analysis to study the associations 
presented. Prospective studies are better because they can establish temporality, but 
telomere shortening, according to the biology occurs with age and highly influenced by 
stress from oxidation. Hence although we conducted a cross-sectional study, we have no 
reason to suspect the direction and validity of our estimates. Secondly, the sample 
involved mainly Caucasian (99%) and results may not apply to other race/ethnicities. 
Thirdly, a much larger sample than we used (974) could be helpful in bringing out certain 
unseen effects and make the results more reliable. However, our results were comparable 
to those from other studies with even much smaller sample size. Fourthly, the effect of 
alcohol on telomere length could be even clearer if had analyzed each alcoholic beverage 
separately. We analyzed all alcoholic beverages together because of very low numbers 
reported per alcohol type. Our results were however comparable to other studies which 
used the same approach. It is important that future studies have samples large enough to 
increase reliability of results and also take advantage of the useful information to be 
gained by analyzing each alcohol type separately.  
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4.5 CONCLUSION 
Telomeres consist of nucleotide repeats that cap the ends of chromosomes and are 
essential to maintaining chromosomal integrity. Telomere shortening has been implicated 
in disease including Down syndrome, Alzheimer’s disease, some cancers, coronary heart 
disease, stroke, myocardial infarctions, and atherosclerosis. Healthy lifestyle factors such 
as non-current smoking, maintaining a healthy body weight, engaging in regular 
moderate or vigorous physical activities, drinking alcohol in moderation, and eating a 
healthy diet have been found to reduce telomere attrition. The opposite of these promote 
increased oxidative stress and inflammation, which enhances white blood cell turnover 
resulting in increased rate of telomere erosion per cell division. Although age and gender 
have strong effects on telomere length as seen in this analysis, they are not modifiable. 
However the rate of attrition can be reduced by lifestyle choices that will minimize the 
oxidative burden on telomeres. In light of these results, a lot needs to be done in 
educating the public to take seriously those activities that lower the risk of telomere loss 
and promote a healthy life. 
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Table 16: Characteristics of Study Participants by Leucocyte Telomere length 
  Leucocyte Telomere Length (kbp)  
  Quartile 1 Quartile 2 Quartile 3 Quartile 4  
VARIABLE N N=243 N=244 N=243 N=244 F  (P-value) 
       
BMI (mean, s.d) 974 28.6 (5.4) 28.0 (5.2) 27.5 (4.7) 27.7 (5.5) 4.88 (0.0274) 
AGE (mean, s.d) 973 61.4 (8.7) 59.3 (8.7) 57.9 (8.2) 54.1 (8.0) 94.25 (<.0001) 
       
BMI      X2  (P-value) 
Normal 293 63 (21.5) 67 (22.9) 74 (25.3) 89 (30.4)  
Overweight 399 98 (24.6) 107 (26.8) 105 (26.3) 89 (22.3)  
Obese 282 82 (29.1) 70 (24.8) 64 (22.7) 66 (23.4) 10.11 (0.1200) 
       
AGE       
<50 149 20 (13.4) 29 (19.5) 30 (20.1) 70 (47.0)  
50-59 429 84 (19.6) 100 (23.3) 121 (28.2) 124 (28.9)  
60-69 276 88 (31.9) 81 (29.4) 71 (25.7) 36 (13.0)  
≥70 119 51(42.9) 34 (28.6) 21 (17.7) 13 (10.9) 100.96(<.0001) 
       
SEX       
Male 473 135 (28.5) 130 (27.5) 111 (23.5) 97 (20.5)  
Female 500 108 (21.6) 114 (22.8) 132 (26.4) 146 (29.2) 15.01 (0.0018) 
       
BLOOD PRESSURE       
Normal 276 50 (18.1) 68 (24.6) 70 (25.4) 88 (31.9)  
Prehypertension 301 77 (25.6) 71 (23.6) 79 (26.2) 74 (24.6)  
Hypertension 397 116 (29.2) 105 (26.4) 94 (23.7) 82 (20.7) 17.41 (0.0079) 
       
CIGARETTE       
Non-smoker 270 69 (25.6) 64 (23.7) 67 (24.8) 70 (25.9)  
Former smoker 514 130 (25.3) 131 (25.5) 124 (24.1) 129 (25.1)  
Current smoker 124 32 (25.8) 33 (26.6) 32 (25.8) 27 (21.8) 1.10 (0.9815) 
       
ENERGY 
EXPENDITURE 
      
1st Quartile 225 59 (26.2) 53 (23.6) 58 (25.8) 55 (24.4)  
2nd Quartile 225 54 (24.0) 55 (24.4) 60 (26.7) 56 (24.9)  
3rd Quartile 225 59 (26.2) 61 (27.1) 49 (21.8) 56 (24.9)  
4th Quartile 225 51(22.7) 56 (24.9) 61 (27.1) 57 (25.3) 3.07 (0.9614) 
       
ALCOHOL       
None 340 94 (27.7) 78 (22.9) 84 (24.7) 84 (24.7)  
1-5 Drinks/week 304 66 (21.7) 73 (24.0) 75 (24.7) 90 (29.6)  
6-13 Drinks/week 192 49 (25.5) 50 (26.0) 48 (25.0) 45 (23.5)  
≥14 Drinks/week 125 34 (27.2) 37 (29.6) 33 (26.4) 21 (16.8) 10.57 (0.3061) 
       
BEER        
None 675 177 (26.2) 160 (23.7) 164 (24.3) 174 (25.8)  
1 Drink/week 94 18 (19.2) 26 (27.7) 23 (24.5) 27 (28.7)  
2-4 Drinks/week 103 24 (23.3) 23 (22.3) 35 (34.0) 21 (20.4)  
≥5 Drinks/week 97 24 (24.7) 32 (33.0) 20 (20.6) 21 (21.7) 11.51 (0.2424) 
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Table 16: Characteristics of Study Participants by Leucocyte Telomere length (continued) 
  Leucocyte Telomere Length (kbp)  
  Quartile 1 Quartile 2 Quartile 3 Quartile 4  
VARIABLE N N=243 N=244 N=243 N=244 X2  (P-value) 
RED WINE       
None 720 184 (25.6) 176 (24.4) 176 (24.4) 184 (25.6)  
1 Drink/week 102 21 (20.6) 28 (27.5) 26 (25.5) 27 (26.5)  
2-4 Drinks/week 85 20 (23.5) 23 (27.1) 24 (28.2) 18 (21.2)  
≥5 Drinks/week 65 18 (27.7) 17 (26.2) 16 (24.6) 14 (21.5) 3.09 (0.9605) 
       
WHITE WINE        
None 658 173 (26.3) 164 (24.9) 159 (24.2) 162 (24.6)  
1 Drink/week 127 27 (21.3) 38 (29.9) 31 (24.4) 31 (24.4)  
2-4 Drinks/week 118 27 (22.9) 26 (22.0) 31 (26.3) 34 (28.8)  
≥5 Drinks/week 67 16 (23.9) 15 (22.4) 21 (31.3) 15 (22.4) 5.50 (0.7887) 
       
OTHERS        
None 690 174 (25.2) 165 (23.9) 176 (25.5) 175 (25.4)  
1 Drink/week 105 20 (19.0) 28 (26.7) 22 (21.0) 35 (33.3)  
2-4 Drinks/week 88 22 (25.0) 28 (31.8) 23 (26.1) 15 (17.1)  
≥5 Drinks/week 83 27 (32.5) 20 (24.1) 19 (22.9) 17 (20.5) 12.26 (0.1992) 
Leucocyte Telomere Length: Quartile 1 (<6.560); Quartile 2 (6.560- 6.953); Quartile 3 (6.954- 7.387); 
Quartile 4 (>7.387). 
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Table 17: Regression estimates of the factors affecting telomere length 
Parameter Estimate Standard 
Error 
t Value Pr >|t| 
Age -0.0211 0.0020 -10.61 <.0001 
     
Sex (M) -0.1167 0.0361 -3.24 0.0012 
     
BMI -0.0080 0.0034 -2.38 0.0176 
     
Alcohol use -0.0047 0.0024 -2.00 0.0454 
 
 
Table 18: Regression estimates of the factors affecting telomere length 
Parameter Estimate Standard Error t Value Pr >|t| 
Age -0.0211 0.0021 -10.08 <.0001 
     
Sex (M) -0.1085 0.0377 -2.88 0.0041 
     
BMI -0.0085 0.0035 -2.40 0.0164 
     
Alcohol use -0.0040 0.0024 -1.65 0.0983 
Smoking     
Non-smoker Referent    
     
Former smoker 0.0162 0.0416 0.39 0.6969 
     
Current smoker -0.0669 0.0603 -1.11 0.2672 
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Table 19: Estimates of the factors affecting telomere length (variables as categories) 
Parameter N Estimate Standard 
Error 
t Value Pr >|t| 
AGE      
<50 149 Referent    
50-59 429 -0.200 0.055 -3.67 0.0003 
60-69 276 -0.425 0.059 -7.24 <.0001 
≥70 119 -0.596 0.070 -8.44 <.0001 
      
SEX      
Male 473 -0.103 0.038 -2.69 0.0073 
Female 500 Referent    
      
BMI      
Normal 293 Referent    
Overweight 399 -0.074 0.045 -1.64 0.102 
Obese 282 -0.113 0.048 -2.34 0.019 
      
ALCOHOL      
0-5 Drinks/week 644 Referent    
6-13 Drinks/week 192 -0.018 0.047 -0.39 0.700 
≥14 Drinks/week 125 -0.093 0.056 -1.66 0.098 
      
Smoking      
Non-smoker 270     
Former smoker 514 0.009 0.042 0.22 0.826 
Current smoker 124 -0.069 0.061 -1.14 0.255 
 
 
 
95 
 
CHAPTER FIVE 
 
SUMMARY AND CONCLUSION 
 
5.1 Oxidative Stress 
All aerobic organisms require oxygen for survival. During metabolism oxygen is 
used to produce ATP and water. The mitochondrion is the site of metabolism and 
dysfunction results in impairment of the electron transport chain producing conducive 
environment for reactive oxygen species. Reactive oxygen species include superoxide 
(O2•-), hydrogen peroxide (H2O2), hydroxyl radical (OH•), hydroxyl ion (OH-), and nitric 
oxide (NO•). Reactive oxygen species can be produced at other sites by different 
enzymes, apart from the mitochondria. These include NADPH oxidase at the plasma 
membrane, lipid oxidation within peroxisomes, and xanthine oxidase in the cytoplasm.  
Living cells are equipped with defense mechanisms to lessen the harmful effects 
of reactive oxygen species. Superoxide dismutase (SOD) catalyzes the conversion of 
superoxide anions into hydrogen peroxide and oxygen. In the peroxisomes of eukaryotic 
cells, the enzyme catalase converts hydrogen peroxide to water and oxygen, completing 
the detoxification that was started by SOD. Catalase is more active when levels of 
hydrogen peroxide are low. Another group of enzymes called glutathione peroxidase 
catalyze the detoxification of hydrogen peroxides when present at high concentrations. 
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The proper functioning of these antioxidant enzymes depends on the availability of 
micro-nutrients such as iron, copper, zinc, and selenium. Dietary antioxidants including 
vitamins E, C, and D, flavonoids and carotenoids are also known to reduce or inhibit 
formation of reactive oxygen species. Accelerated reactive oxygen species production 
occurs when micro-nutrients that are important for antioxidant enzyme function, and 
dietary antioxidants are exhausted. This imbalance between the cell’s defense systems 
and reactive oxygen species is known as oxidative stress. 
Oxidative stress causes oxidative damage resulting in cell injury. Oxidative 
damage to DNA can cause DNA mutation leading to changes in protein gene expression. 
Protein modifications caused by reactive oxygen species have been found in elevated 
levels in diseased tissues in patients with inflammatory diseases. Lipids also undergo 
peroxidation in the presence of reactive oxygen species. Lipid peroxidation initiates the 
formation of plaques in the arteries with time giving rise to atherosclerosis. Lipid 
peroxidation is one of the most widely used indicators of oxidative stress. Oxidative 
stress has been implication in diabetes, Parkinson’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington disease, cancer, and cardiovascular disease.  
Lifestyle factors such as overweight and obesity, cigarette smoking, excessive 
alcohol consumption, and inactivity have been associated with increased oxidative stress.  
Obesity is accumulation of excess fat in the adipose tissue resulting in alteration in 
secretion of adipokines and cytokines. Obesity is characterized by high levels of 
circulating free fatty acids, decreased antioxidant defenses and chronic inflammation and 
hence enhanced oxidative stress. Cigarette smoke contains a large variety of compounds, 
including oxidants and free radicals, and alcohol could induce inflammation impair 
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antioxidant systems. Physical activity is important in utilizing ATP and prevents the 
harboring of electrons in the electron transport chain. Inactivity therefore promotes the 
harboring of excess electrons in the transport chains leading to reactive oxygen species 
production and hence oxidative stress.   
 
5.2 Sleep Disordered Breathing 
Sleep-Disordered breathing (SDB) describes a group of disorders characterized by 
inadequate ventilation or abnormal breathing during sleep. It involves total or partial 
collapse of the pharyngeal airway during sleep necessitating arousal to resume 
ventilation. The intermittent hypoxia followed by reoxygenation has been associated with 
reactive oxygen species production. Several studies have also shown that plasma levels of 
lipid peroxidation biomarkers such as thiobarbituric reactive substances (TBARS) and 
peroxides (PD) were significantly higher among sleep apnea patients than normal 
controls. Since lipid peroxidation plays a key role in the formation of atherosclerosis 
plaques, SDB patients have been found to be at greater risk of atherosclerosis and 
mortality from cardiovascular diseases. This study investigated the association between 
SDB and CML concentration and found that participants with SDB have higher CML 
levels than participants without SDB, within certain hemoglobin ranges. High CML 
concentration is an indication of oxidative stress. Some participants with SDB have been 
found to have lower CML concentration which has been attributed to their physical 
fitness because moderate to high physical activity has been associated with reduced 
oxidative stress. It should also be noted that we studied an older population (mean age 
77.5 years) and most males with severe SDB may have died before CML was measured.  
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The lower CML values found among males who have survived may not be a protective 
effect of severe SDB but may be due other reasons not assessed in this study. CML 
values from a younger population may be important in understanding the relationship 
between SDB and CML concentration.  Part of this dissertation also looked at sleep 
disturbances and type-2-diabetes. As described above sleep disturbances have oxidative 
stress consequences. The β-cells of the pancreas lack catalase and are vulnerable to the 
toxic effects mediated by reactive oxygen species. Findings from this study indicated 
higher risk of type-2-diabetes among subjects with poor sleep quality which was further 
exacerbated by obesity.  Hence taken together, these observations emphasize the 
importance of SDB in oxidative stress and its consequences.  
 
5.3 Carboxymethyl-lysine (CML) 
Advanced glycation end-products (AGEs) are a heterogeneous group of 
macromolecules that are formed by the non-enzymatic glycation of proteins, lipids, and 
nucleic acids. CML is a dominant AGE and is formed on protein by combined non-
enzymatic glycation and oxidation (glycoxidation) reactions. It is also formed during 
lipid peroxidation (metal-catalyzed oxidation of polyunsaturated fatty acids in the 
presence of protein. Lipids undergo peroxidation in the presence of reactive oxygen 
species. Hence Lipid peroxidation is one of the most widely used indicators of oxidative 
stress. Since CML is formed from lipid peroxidation, it has been characterized as the 
general biomarker of oxidative stress. CML has therefore been associated with many of 
the disorders known to be related to oxidative stress including Parkinson’s disease, 
Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington disease, rheumatoid 
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arthritis, end-stage renal disease, hypertension, atherosclerosis, and cardiovascular 
disease.  The importance of studying the association between CML and SDB is to 
establish grounds for preventive measures. SDB treatment by use of CPAP has been 
successful hence in order to reduce CML concentration and prevent disease, treatment of 
sleep problems could be considered among the many strategies.  
 
5.4 Telomeres 
Telomere attrition has been implicated in diseases including cancer, diabetes, 
hypertension, atherosclerosis, coronary artery disease, and chronic heart failure. 
Telomeres shorten at each cell division until a threshold is reached where no further 
replication can take place (cellular senescence). Telomere length therefore depends on 
age but shortening can be accelerated by oxidative stress.  Oxidative stress and 
inflammation enhances white blood cell turnover resulting in increased rate of telomere 
erosion per cell division. Lifestyle factors such as current smoking, overweight and 
obesity, sedentary lifestyle, excessive alcohol consumption, and unhealthy diet have been 
found to increase telomere attrition. Public health messages directed towards these 
lifestyle factors may go a long way to promote good health and longevity. 
 
5.5 Aging and Age-related Diseases 
Since proposed by Harman in 1956, the free radical theory remained the most 
popular theory of aging and age-related diseases. As mentioned above, oxidative stress 
contributes to telomere shortening and therefore places limit on the replicative potential 
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of the cell. Loss of replicative potential leads to cellular senescence. CML concentrations 
were also higher with increased oxidative stress. According to Harman the accumulation 
of the impact of oxidative stress on cells over time contribute to the aging of the 
organism. Both high CML concentration and shortened telomeres are very dependent on 
age and are associated with degenerative diseases. Since the mitochondria produces most 
of the reactive oxygen species, is has been proposed that the higher the metabolic rate of 
an organism the greater the production of reactive oxygen species and hence the shorter 
the life span of the organism. In response to this hypothesis, a strategy like caloric 
restriction has been proposed as a way to reduce oxidative damage and disease. As shown 
in this study, sleep hygiene is something to consider in the policy framework of 
interventions aimed at aging and degenerative diseases. Other healthy lifestyle factors to 
consider include maintaining a healthy weight, smoking cessation, moderation in alcohol 
consumption, and moderate to high physical activity.   
 
5.6 Recommendations for Future Research 
The biology of oxidative stress and health have been received a lot of attention 
since the 1950s yet there is still much to be known on the topic. Inflammation and 
oxidative stress factors have been associated with telomere length in this study and 
oxidative stress from sleep disordered breathing has been associated with CML 
concentration. Telomere shortening and CML concentration have been implicated in 
degenerative diseases but the association between them is yet to be studied. Future 
studies may investigate this association to determine if shorter telomeres are associated 
with high CML concentrations or vice-versa. Further studies are also needed to verify if 
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higher CML concentration as a result of SDB is actually associated with a disease 
outcome in the CHS. Furthermore, the association between hemoglobin, SDB, and CML 
needs to be replicated with a much larger sample and if possible longitudinally. 
Specifically, a future study could focus on investigating the protective effect of SDB on 
CML concentration among males with high hemoglobin.
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